

CURRICULUM VITAE

HAROLD STANLEY NELSON, M.D.

17 January 2024



Date and Place of Birth:

January 17, 1930, New Britain, Connecticut

High School:

Miami Edison Senior High School, Miami, Florida, Graduate 1947

Undergraduate:

Harvard College, AB, Economics, 1951

Medical School:

Emory University, Atlanta, Georgia, MD, 1955

Graduate School:

University of Michigan, MS, 1969

Internship:

Atlanta Veterans Administration Hospital, Atlanta, Georgia, 1955-56

Residency:

Letterman General Hospital, San Francisco, California, Internal Medicine, 1959-62

Fellowships:

Allergy-Immunology, University of Michigan Medical Center, Ann Arbor, Michigan, 1967-69, MS, University of Michigan, 1969

Additional Training:

Fellowship in Tropical Medicine, Louisiana State University, New Orleans, Louisiana, 1963 (2 months)

Certification by Specialty Board:

American Board of Internal Medicine, 1963;
American Board of Allergy-Immunology, 1970;
Recertified in Allergy-Immunology 1977, 1983

Professional Societies:

American Academy of Allergy, Asthma and Immunology (Fellow) 1972;
American College of Allergy, Asthma and Immunology (Fellow) 1979;
Colorado Allergy Society
Western Society of Allergy, Asthma and Immunology

Licenses:

Colorado 18391

Military Service:

United States Army Medical Corps, 1956-86
Colonel, 1971-86
Chief, Allergy-Immunology Service, Fitzsimons Army Medical Center, Aurora, Colorado, 1969-86

Head, Allergy-Immunology training program 1971-86
Consultant to the Surgeon General in Allergy and Clinical Immunology, 1981-86

Present Employment:

Professor of Medicine, Department of Medicine, National Jewish Health Center, 1400 Jackson Street, Denver, Colorado, 80206, July 1986 - present

Teaching Appointments:

1987 - Professor of Medicine, University of Colorado School of Medicine, Denver, Colorado.
1982 - 1987 Clinical Professor of Medicine, University of Colorado School of Medicine, Denver, Colorado.
1972 - 1982 Clinical Associate Professor of Medicine (Immunology).
1987 - 1989 Acting Head, Allergy-Immunology Division, Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado,
1971-1986 Director Allergy-Immunology training program Fitzsimons Army Medical Center

Offices and Committees:

1987 - 1989 Co-Director, Allergy-Immunology Training Program, University of Colorado School of Medicine, Denver, Colorado
2001- 2005 Co-Director, Weinberg Clinical Research Unit

CME - Courses:

Course Director: Fitzsimmons Allergy Symposium, 1971-86
Course Director: National Jewish update on Clinical Allergy and Immunology, 1987-1999
Co-director 2000-present
Aspen Allergy Conference Steering Committee, 1982 - present.
Co-director, Comprehensive Review in Adult & Pediatric Allergy/Immunology, 1991-5

NIH: National Heart, Lung, Blood Institute:

Member Expert Panel on the Diagnosis Management of Asthma for the National Asthma Education Program of the National Heart, Lung and Blood Institute, 1989 - 1991.
Member Executive Committee Expert Panel to update "Guidelines for the Diagnosis and Management of Asthma" Chair, Subcommittee on Environmental Control, 1995 - 1997.
Working Group on Asthma and Pregnancy of the National Asthma Education Program of the National Heart, Lung and Blood Institute, 1991-1992.
Science Base Committee Section on Prevention, 1994 - 1995.
Chairman - Special Emphasis Panel on Asthma Prevention, 1995.
NAEPP Science Based Committee, 1999-present
Working Group, Guidelines for Treatment of Asthma in Pregnancy, 2002-3
Member Expert Panel 3, Chair Subcommittee on Factors making asthma worse. 2004-14
Member NHLBAC Asthma Expert Working Group 2014-6

American Academy of Allergy, Asthma and Immunology:

Member Ethics Committee 1979 - 82;
Seminars Committee 1980 - 83;
Editorial Board of The Journal of Allergy and Clinical Immunology 1980-85; 1992 - 97
Postgraduate Education Committee 1983 - 86;
Chairman, Committee on Environmental Control and Air Pollution 1985-88
Practice Standards Committee 1987 - 92
Co-Chairman Committee on Remote Practices 1988 - 89
Chairman, Subcommittee of Remote Practices 1990 - 92
Committee on Diagnostic Technique 1992
Anti-inflammatory Committee 1994
Skin Test Proficiency Programs Committee 1993 - 1995
Board of Directors 1996 - 1999
Asthma and Allergic Diseases Management Center (AADMC) website advisory committee, 1997
Asthma and Related Diseases Interest Section, Secretary 1995-97; Vice Chairman 1997-99, Chair 1999-2001
Abstract Review Committee, 1997-2001
Immunotherapy and Allergy Diagnostics Committee (2004-24)

Asthma Pharmacotherapeutics Committee (2008-9)

Deputy Editor, Journal of Allergy and Immunology 1998-2008

Program Committee, 1994-2001

Health Care Delivery and Quality Planning Committee, 2000 - 2002

Immunotherapy, 1999-2004

Task Force on Allergic disorders: Promoting Best Practice. Co-Chair (1998 – 2000)

Allied health Annual Meeting Subcommittee (Clinical Research work Group) 2003

Methodology Committee (2005-7)

Asthma Diagnosis, Assessment and Treatment (2010-15)

Immunotherapy, allergen standardization and allergy diagnostics Committee (2014-2024)

American Board of Allergy and Immunology:

Board of Directors 1984 - 89;

Treasurer 1984 - 1988

Co-Chair, Certifying Examination Committee, 1987 - 89

American College of Allergy and Immunology:

Secretary 1982 - 83

Second Vice President 1983 - 84

Program Committee 1983 – 1997, 2005

Board of Regents 1984 - 87

Editorial Board of Annals of Allergy 1979 - 89, 1992 - 1996

Annals Council 1981 - 82; 1984 - 85

Practice Standards Committee 1986 - 89

Ethics Committee 1988 - 90

Professional Education Council 1988 - 89

Speakers' Bureau 1988 - 89

Chairman Abstracts Committee 1983 - 1997

Allergy Journal Club 1993 - 1999

Professional Education 1990 - 1997

Publications Committee 1996 - 1999

Immunotherapy Committee, 1997 – 98

World Allergy Organization:

Immunotherapy Committee (2007-9)

Asthma Committee (2007-9)

American Medical Association:

Member, Physician Consortium For Performance Improvement – Asthma Work Group, 1999-2000

Asthma and Allergy Foundation of America

Vice President, Medical Affairs, 1997-1999

Chair, Medical Scientific Council, 1997-1999

Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee of the Food and Drug Administration, 1988-1992.

Consultant for the Food and Drug Administration, 1992-1997.

Allergenic Products Advisory Committee of the Food and Drug Administration, 2001-2005.

United States Pharmacopeial Convention

Committee of Revision, 1990-1995, 1995-2000.

Chairman: Pulmonary Disease Advisory Panel, 1990-1995, 1995-2000.

Joint Council of Allergy, Asthma and immunology.

Joint Academy/College/JCAAI Sublingual Immunotherapy Committee 2005-6

Awards & Honors:

American College of Allergy and Immunology

Bela Schick Lecturer, 1985
Fellow, Distinguished Award, 1986
Jaros Lecturer, 1989
McGovern Lecturer, 1990
Lester Mittelstaedt Lecturer, 1995
1st Annual Gold-Headed Cane Award, 2001 – for lifetime achievement
Harold S. Nelson Lectureship at annual meeting 2008 and 2009.

American Academy of Allergy, Asthma and Immunology

Distinguished Clinician Award, 1996
Harold S. Nelson Lectureship at annual meeting. (2001-2017)
2005 Distinguished Service Award
Special Recognition Award 2008
Harold S Nelson Lectureship, annual meeting, 2020-2024.

Royal College of Physicians

Member (2001- 2022)

National Jewish Medical and Research Center

Teacher of the Year Award (2005)
Life-time Achievement Award (2006)
Harold S Nelson Keystone Lecture at the National Jewish Health Pulmonary & Allergy Update, Keystone Resort (2024-)

World Allergy Organization

Outstanding Clinician Award (2007)

Association of Military Allergists

Annual meeting named the Harold S. Nelson Military Allergy/immunology Symposium (1986-present)

Western Society of Allergy, Asthma and Immunology

Harold S. Nelson MD lecture at annual meeting (2018-2022)

1989 James J. Waring Award. American Lung Association of Colorado for "Advancement Of Medical And Scientific Information in the Area of Lung Disease."

Listed "Best Doctors" 1993-2004.

Castle Connolly Medical Ltd: America's Top Doctors 1st Edition 2001; 2nd Edition 2002; 3rd Edition 2003; 4th Edition 2004, 5th Edition 2005. 6th edition 2006, 7th edition 2007, 8th edition 2008

Consumers' Research Council of American "Guide to America's Top Physicians" 2011 & 2012 Editions.

PUBLICATIONS:

Peer Reviewed

1. Bacharach T, Nelson HS: Secondary pneumonia. JAMA 1962;181:1135.
2. Nelson HS: Delayed hypersensitivity in cancer patients: Cutaneous and in vitro lymphocyte response to specific antigens. J Natl Cancer Inst 1969;42:765.
3. Newcomb RW, Nelson HS: Dermographia mediated by immunoglobulin E. Am J Med 1973;54:174.
4. Nelson HS: The effect of ephedrine on the response to epinephrine in normal men. J Allergy Clin Immunol 1973;51:191.
5. Nelson HS, Black JW, Branch LB, Pfuetze B, Spaulding H, Summers D, Wood D: Subsensitvity to epinephrine following the administration of epinephrine and ephedrine to normal individuals. J Allergy Clin Immunol 1975;55:299.
6. Nelson HS, Brown G, O'Barr TP, Branch LB, Spaulding H, Black JW: Clinical and immunological studies of timothy antigen D immunotherapy. J Allergy Clin Immunol 1976;57:463.
7. Nelson HS, Raine D, Branch LB: Beta-adrenergic subsensitivity induced by chronic administration of terbutaline. Int Arch Allergy Appl Immunol 1977;55:362.
8. Posey WC, Nelson HS: Controlled trials with four percent cromolyn spray in seasonal allergic rhinitis. Clin Allergy 1977;7:485.
9. Nelson HS, Branch LB: The relation of serum IgA and delayed hypersensitivity skin tests to serum IgE levels. Ann Allergy 1977;39:113.
10. Kalisker A, Nelson HS, Middleton E: Drug induced changes of adenylate cyclase activity in cells from asthmatic and non-asthmatic subjects. J Allergy Clin Immunol 1977;60:259.
11. Nelson HS, Branch LB: Incidence of IgG short-term sensitizing antibodies in an allergic population. J Allergy Clin Immunol 1977;60:266.
12. Nelson HS, Raine D Jr., Doner HC, Posey WC: Subsensitvity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis 1977;116:871.
13. Stein MR, Brown GL, Lima JE, Nelson HS, Carr RI: A laboratory evaluation of immune complexes in patients on inhalant immunotherapy. J Allergy Clin Immunol 1978;62:211.
14. Posey WC, Nelson HS, Branch LB, Pearlman DS: The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978;62:340.
15. Weber R, Nelson HS, Petty WE: Aerosolized terbutaline in asthmatics: A comparison of dosage strength, schedule, and method of administration. J Allergy Clin Immunol 1979;63:116.
16. Nelson HS: The effect of preservatives and dilution on the deterioration of a pollen extract - Russian thistle (Salsola pestifer). J Allergy Clin Immunol 1979;63:417.
17. de Shazo RD, Nelson HS: An approach to the patient with a history of local anesthetic hypersensitivity: Experience with 90 patients. J Allergy Clin Immunol 1979;63:387.
18. Weber RW, Hoffman M, Raine DA, Nelson HS: Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32.
19. Smith JA, Mansfield LE, Nelson HS: The effect of cimetidine on the immediate cutaneous response to allergens. Ann Allergy 1979;42:353.

20. Smith JA, Mansfield LE, de Shazo RD, Nelson HS: An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. *J Allergy Clin Immunol* 1980;65:118.
21. Jacobson KW, Branch LB, Nelson HS: Laboratory tests in chronic urticaria. *JAMA* 1980;243:1644.
22. Dantzer BS, Tipton WR, Nelson HS, O'Barr TP: Tissue threshold changes during the first months of immunotherapy. *Ann Allergy* 1980;45:213.
23. Stein MR, Towner TG, Weber RW, Mansfield LE, Jacobson KW, McDonnell JT, Nelson HS: The effect of theophylline on the lower esophageal sphincter pressure. *Ann Allergy* 1980;45:238.
24. Smith JA, Weber RW, Nelson HS: Double-blind comparison of optimal dose theophylline and aerosolized terbutaline in the treatment of bronchial asthma. *Chest* 1980;78:816.
25. Nelson HS: Long-term immunotherapy with aqueous and aluminum-precipitated grass extracts. *Ann Allergy* 1980;45:333.
26. Nelson HS: The effect of preservatives and conditions of storage on the potency of allergy extracts. *J Allergy Clin Immunol* 1981;67:64.
27. Tipton WR, Jacobson KW, Nelson HS, Souhrada JF, Morris HG: Dynamics of isoproterenol subsensitivity in the guinea pig trachea. Comparison of tissue cAMP levels and smooth muscle relaxation. *Lung* 1981;159:199.
28. Fortner BR Jr, Dantzer BS, Tipton WR, Nelson HS: The effect of weekly versus monthly ragweed allergen injections on immunologic parameters. *Ann Allergy* 1981;47:147.
29. Tipton WR, Nelson HS: Experience with daily immunotherapy in 59 adult allergic patients. *J Allergy Clin Immunol* 1982;69:194.
30. Mansfield LE, Nelson HS: Allergens in commercial house dust. *Ann Allergy* 1982;48:205.
31. Mansfield LE, Nelson HS: Effect of beta-adrenergic agents on immunoglobulin-G levels in asthmatic subjects. *Arch All Appl Immunol* 1982;68:13.
32. Fortner BR Jr., Danzinger RE, Rabinowitz PS, Nelson HS: The effect of ascorbic acid on cutaneous and nasal response to histamine and allergen. *J Allergy Clin Immunol* 1982;69:484.
33. Weber RW, Smith JA, Nelson HS: Aerosolized terbutaline in asthmatics: Development of subsensitivity with long-term administration. *J Allergy Clin Immunol* 1982;70:417.
34. Wagner CJ, Taylor RJ, Nelson HS: Liability of blocking antibody during ragweed immunotherapy. *Ann Allergy* 1983;50:19.
35. Leavengood DC, Bunker-Soler AL, Nelson HS: The effect of corticosteroids on theophylline metabolism. *Ann Allergy* 1983;50:249.
36. Mansfield LE, Smith JA, Nelson HS: Greater inhibition of dermographia with a combination of H₁ and H₂ antagonists. *Ann Allergy* 1983;50:264.
37. Carpenter GB, Bunker-Soler AL, Nelson HS: Evaluation of combined H₁- and H₂-receptor blocking agents in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1983;71:412.
38. Smith JA, Mansfield LE, Fokakis A, Nelson HS: Dermographia caused by IgE mediated penicillin allergy. *Ann Allergy* 1983;51:30.

39. Nelson HS, Spector SL, Whitsett TL, George RB, Dwek JH: The bronchodilator response to inhalation of increasing doses of aerosolized albuterol. *J Allergy Clin Immunol* 1983;72:371.
40. Wagner CJ, Danziger RE, Nelson HS: Relation between positive small air ions, weather fronts, and pulmonary function in patients with bronchial asthma. *Ann Allergy* 1983;51:430.
41. Dantzer BS, Martin BG, Nelson HS: The effect of positive and negative air ions on bronchial asthma. *Ann Allergy* 1983;51:362.
42. Mansfield LE, Nelson HS, Schur PH: IgG subclasses in asthmatic patients. *J Asthma* 1983;20:189.
43. Venter JC, Fraser CM, Nelson HS, Middleton E Jr.: Adrenergic agents. In: *Allergy: Principles and Practice*, Vol. 1, 2nd Edition, Eds. E Middleton Jr, CE Reed, EF Ellis. St. Louis, The C. V. Mosby Company, 1983.
44. Andrade WP, Renard RL, Nelson HS: The effect of troleandomycin and methylprednisolone alone and in combination on bronchial sensitivity to methacholine. *Ann Allergy* 1983;51:515.
45. Weber RW, Nelson HS: Pirbuterol hydrochloride: Evaluation of beta adrenergic agonist activity in reversible obstructive pulmonary disease and congestive heart failure. *Pharmacotherapy* 1984;4:1.
46. Nelson HS: Combination of oral theophylline and aerosolized beta₂-agonists. In: Jonkman JHG, Jenne JW, Simons FER Editors. *Sustained Release Theophylline in the Treatment of CRAO*. International Workshop, Mont Ste Marie, Canada, *Excerpta Medica* 1984;p.181-187.
47. Martin BG, Mansfield LE, Nelson HS: Cross-allergenicity among the grasses. *Ann Allergy* 1985;54:99.
48. Moyer DB, Nelson HS: Use of modified radioallergosorbent testing in determining initial immunotherapy doses. *Otolaryngol Head Neck Surg* 1985;93:335.
49. Taylor RJ, Long WF, Nelson HS: The development of subsensitivity to chlorpheniramine. *J Allergy Clin Immunol* 1985;76:103.
50. Long WF, Taylor RJ, Leavengood DC, Nelson HS: Skin test suppression by antihistamines and the development of subsensitivity. *J Allergy Clin Immunol* 1985;76:113.
51. Kray KT, Squire EN, Tipton WR, O'Dea J, Nelson HS: Cromolyn sodium in seasonal allergic conjunctivitis. *J Allergy Clin Immunol* 1985;76:623-627.
52. Moyer DB, Nelson HS, Arlian LG: House dust mites in Colorado. *Ann Allergy* 1985;55:680.
53. Leavengood DC, Renard RL, Martin BG, Nelson HS: Cross allergenicity among grasses determined by tissue threshold changes. *J Allergy Clin Immunol* 1985;76:789.
54. Brown JS, Ledoux RA, Nelson HS: An investigation of possible immunologic reactions to human serum albumin used as a stabilizer in allergy extracts. *J Allergy Clin Immunol* 1985;76:808.
55. Squire EN, McBride DC, Ledoux R, Nelson HS: Assessment of IgE mediated sensitivity during immunotherapy; Comparison of the RAST with and without adsorption of IgG to titrated prick skin. *Ann Allergy* 1986;56:72;.
56. Vandewalker ML, Kray KT, Weber RW, Nelson HS: Addition of terbutaline to optimal theophylline therapy: Double-blind crossover study in asthmatic patients. *Chest* 1986;90:198.
57. Squire EN Jr, Nelson HS: Corticosteroids and theophylline clearance. *NER Allergy Proc* 1987;8:33-35.
58. Tipton WR, Nelson HS: Frequent parenteral terbutaline in the treatment of status asthmaticus in children. *Annals of Allergy* 1987;58:252-256.

59. Bantz EW, Dolen WK, Nelson HS: A double-blind evaluation of skin test suppression produced by two doses of terfenadine. *J Allergy Clin Immunol* 1987;80:99.
60. Bantz EW, Dolen WK, Chadwick EW, Nelson HS: Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance. *Ann Allergy* 1987;59:341.
61. Dolen WK, Miller BT, Ledoux RL, Seltzer JM, Wiener MB, Selner JC, Nelson HS: Comparison of parallel line skin test assay and ELISA inhibition methods for determination of relative potency of prolimerized grass and ragweed antigenic extracts. *J Allergy Clin Immunol* 1988;81:489-493.
62. Vaughan TF, Bowen RE, Goodman DL, Weber RW, Nelson HS: The development of subsensitivity to atropine methylnitrate: a double-blind, placebo-controlled crossover study. *Am Rev Respir Dis* 1988;138:771.
63. Nelson HS, Hirsch SR, Ohman JL Jr, Platts-Mills TAE, Reed CE, Solomon WR: Recommendations for the use of residential air-cleaning devices in the treatment of allergic respiratory diseases. *J Allergy Clin Immunol* 1988;82:661.
64. Zurich KM, Nelson HS, Patel A, Bodman S, Gilner D, Winder J: The effect of theophylline and enprofylline on the late cutaneous response to antigen and compound 48/80. *J Allergy Clin Immunol* 1989;83:428.
65. Vaughan TR, Weber RW, Tipton WR, Nelson HS: Comparison of PEFR and FEV₁ in patients with varying degrees of airway obstruction: Effect of modest altitude. *Chest* 1989;95:558.
66. Vichyanond P, Nelson HS: Circadian variation of skin reactivity and allergy skin tests. *J Allergy Clin Immunol* 1989;83:1101.
67. Adinoff AD, Rosloniec DM, McCall LL, Nelson HS: A comparison of six epicutaneous devices in the performance of immediate hypersensitivity skin test. *J Allergy Clin Immunol* 1989;84:168.
68. Miller J, Nelson HS: Suppression of immediate skin tests by ranitidine. *J Allergy Clinical Immunology* 1989;84:895-899.
69. Vichyanond P, Sladek WA, Sur S, Hill MR, Szeffler SJ, Nelson HS: Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. *Chest* 1990;98:637-642.
70. Goodman DL, McDonnell JT, Nelson HS, Vaughan TR: Chronic urticaria exacerbated by the anti-oxidant food preservatives, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). *J Allergy Clin Immunol* 1990;86:570-575.
71. Adinoff AD, Rosloniec DM, McCall LL, Nelson HS: Immediate skin test reactivity to Food and Drug Administration-approved standardized extracts. *J Allergy Clin Immunol* 1990;86:766-774.
72. Sur S, Mohiuddin AA, Vichyanond P, Nelson HS: A random double-blind trial of the combination of nebulized atropine methylnitrate and albuterol in nocturnal asthma. *Ann Allergy* 1990;65:384-388.
73. Nelson HS, Skufca RM: Double-blind study of suppression of indoor fungi and bacteria by the PuriDyne biogenic air purifier. *Ann Allergy* 1991;66:263-266.
74. Nelson HS, Szeffler SJ, Martin RJ: Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: Beneficial or Detrimental? *Am Rev Respir Dis* 1991;144:249.
75. Zwetchkenbaum JF, Skufca R, Nelson HS: An examination of food hypersensitivity as a cause of increased bronchial responsiveness to inhaled methacholine. *J Allergy Clin Immunol*, 1991;88(3):360-364.
76. Hollie MC, Malone RA, Skufca RM, Nelson HS: Extreme variability in aerosol output of DeVilbiss 646 jet nebulizer. *Chest*. November, 1991;100:1339-1344.

77. Oppenheimer JJ, Tonnesen MG, Nelson HS: Case report: an unusual reaction to foods. *Annals of Allergy*, 1992;68:17-21.
78. Lavins BJ, Dolen WK, Nelson HS, Weber RW: Use of standardized and conventional allergen extracts in prick skin testing. *J Allergy Clin Immunol* 1992;89:658-666.
79. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DYM: Treatment of peanut allergy with rush immunotherapy. *J Allergy Clinical Immunology*, 1992;90:256-62.
80. Silvers WS, Ledoux RA, Dolen WK, Morrison MR, Nelson HS, Webber RW: Aerobiology of the Colorado Rockies: Pollen count comparisons between Vail and Denver Colorado. *Ann All* 1992;69:421-426.
81. Oppenheimer J, Buchmeier A, Nelson HS: Double-blind trial of a heated nasal aerosol in the treatment of perennial allergic rhinitis. *JACI* 1993;92:56-60.
82. Nelson HS, Areson JG, Reisman R: A prospective assessment of the remote practice of allergy: Comparison of the diagnosis of allergic disease and the recommendations for allergen immunotherapy by board certified allergists and a laboratory performing in vitro assays. *J Allergy Clin Immunol* 1993;92:380-386
83. Oppenheimer J, Nelson HS: Seasonal variation in immediate skin test reactions. *Ann Allergy* 1993;71:227-29.
84. Sur S, Camara M, Buchmeier A, Morgan S, Nelson HS: Double-Blind trial of pyridoxine (Vitamin B6) in the treatment of steroid-dependent asthma. *Ann Allergy* 1993;70:147-52.
85. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL: A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. *Am Rev Respir Dis* 1993;147:398-404
86. Tinkelman DG, Reed CE, Nelson HS, Offord KP: Aerosol Beclomethasone Dipropionate Compared With Theophylline as Primary Treatment of Chronic, Mild to Moderately Severe Asthma in Children. *Pediatrics* 1993;92:64-77.
87. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A: A double-blind, placebo-controlled evaluation of sublingual immuno-therapy with standardized cat extract. *J Allergy Clin Immunol* 1993;92:229-236.
88. Nelson HS, Rosloniec D, McCall LL, Ikle' D: Comparative performance of five commercial prick skin test devices. *JACI* 1993;92:750-6.
89. Malone RA, Holle MC, Glynn-Barnhart A, Nelson HS: Optimal Duration of Nebulized albuterol therapy. *Chest* 1993;104:1114-8
90. Oppenheimer J, Areson JG, Nelson HS: Safety and efficacy of oral immunotherapy with standardized cat extract. *J Allergy Clin Immunol* 1994;93:61-7.
91. Nelson HS, Loffert DT. Comparison of the bronchodilator response to albuterol administered by the OptiHaler, the AeroChamber or by Metered Dose Inhaler alone. *Ann Allergy* 1994;72(4):337-340.
92. Welch MJ, Nelson HS, Paull BR, Smith JA, Feiss G, Tobey RE. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. *Ann Allergy* 1994;72(4):348-352.
93. Loffert T, Ikle D, Nelson H. A comparison of commercial jet nebulizers. *Chest* 1994;106:1788-1792.
94. Nelson HS, Bucher B, Buchmeier A, Oppenheimer, Garcia J. Suppression of the skin reaction to histamine by ebastine. *Ann Allergy* 1995;74:442-447.
95. Leflein J, Brown E, Hill M, Kelly HW, Loffert DT, Nelson HS, Szeffler. Delivery of glucocorticoids by jet nebulization: Aerosol characteristics and output. *J Allergy Clin Immunol* 1995;95:944-949.

96. Wurtzen PA, Nelson HS, Lowenstein H, Ipsen H. Characterization of Chenopodiales (Amaranthus retroflexus, Chenopodium album, Kochia scoparia, Salsola pestifer) pollen agents. *Allergy* 1995;50:489-497.
97. Glassheim JW, Ledoux RA, Vaughan TR, Damiano MA, Goodman DL, Nelson HS, Weber RW. Analysis of meteorologic variables and seasonal aeroallergen pollen counts in Denver, Colorado. *Ann Allergy Asthma Immunol* 1995;75:149.
98. Nelson HS, and Fernandez-Caldas E. Prevalence of housedust mite in the Rocky Mountain States. *Ann Allergy Asthma Immunol* 1995;75:337-339.
99. Nelson HS, Knoetzer M, Bucher B. Effect of distance between sites and region of the body on results of skin prick tests. *JACI* 1996;97:596-601.
100. Nelson HS, Oppenheimer J, Buchmeier A, Kordash TR, Freshwater LL. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to Timothy grass. *JACI* 1996;97:1193-1201.
101. Nelson HS, Ilke' D, Buchmeier A. Studies of allergen extract stability: the effect of dilution and mixing. *J Allergy Clin Immunol* 1996;98:382-388.
102. Newman KB, Mason UG, Buchmeier A, Schmaling KB, Corsello P, Nelson HS. Failure of colchicine to reduce inhaled triamcinolone dose in patients with asthma. *J Allergy Clin Immunol* 1997;99:176-8.
103. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL, Giclas PC, Gelfand EW. Rush Immunotherapy results in allergen-specific alterations and lymphocyte function and interferon gamma production in CD4 positive T-cells. *J Allergy Clin Immunology* 1997;99:530-8.
104. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. *J Allergy Clin Immunology* 1997;99:744-51.
105. Gaglani B, Borish L, Bucher-Bartelson B, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced allergic rhinitis. *Ann Allergy Asthma Immunol* 1997;79:259-65.
106. Reisner C, and Nelson HS: Vocal cord dysfunction with nocturnal awakening. *J. Allergy Clin Immunol.* 99:843-6, 1997
107. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. *J Allergy Clin Immunol* 1998;101:14-23.
108. Nelson HS, Lahr J, Buchmeier A, McCormick D. Evaluation of devices for skin prick testing. *J Allergy Clin Immunol* 1998;101:153-6.
109. Nelson HS, Bernstein IL, Fink JN, Edwards TB, Spector SL, Storms WW, Tashkin DP. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbohaler: A double-blind, placebo-control led study in adults with moderate-to-severe chronic asthma. *Chest* 1998;113:1264-71.
110. Nimmagadda SR, Spahn JD, Nelson HS, Jenkins J, Szeffler SJ, Leung DYM. Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma. *Ann Allergy Asthma Immunol* 1998;81:35-40.
111. Nelson HS, Bensch G, Pleskow W, DeSantostefano R, DeGraw Sidney, Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. *J. Allergy Clin Immunol* 1998;102:6: 943-952

112. Szeffler SJ, Oliver S, Bender B, Nelson H, Culkin C, Taggart V. Design and implementation of a patient education center for the childhood asthma management program. *Ann Allergy Asthma Immunol* 1998;81:571-581
113. Nelson HS, Kemp JP, Bieler S, Vaughan LM, Hill MR. Comparative Efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler. *Chest* 1999;115:329-335
114. Nelson, HS, Busse WW, Bennett P, deBoisblanc MD, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, and Harding SM. Fluticasone propionate powder: Oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. *J Allergy Clin Immunol* 1999;103:267-275.
115. Nelson, HS, Berkowitz, RB, Tinkelman, DA, Emmett, AH, Rickard, KA, Yancey, SW. Lack of Subsensitization to albuterol after treatment with salmeterol in patients with asthma. *Am J Respir Crit Care Med* 1999;159:1556-1561
116. ER McFadden, TB Casale, TB Edwards, JP Kemp, WJ Metzger, HS Nelson, WW Storms, MJ Neidl. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. *J Allergy Clinical Immunology* 1999; 104:46-52
117. Nelson HS, Szeffler SJ, Jacobs J, Huss K, Shapiro G, Sternberg AL. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. *J Allergy Clin Immunol* 1999; 104:775-85
118. Nelson HS. Mechanisms of intranasal steroids in the management of upper respiratory allergic diseases. *J Allergy Clin Immunol* 1999; 104:S138-43
119. Bernstein DI, Berkowitz RB; Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C; Lumry W, Mendelson, LM, Nelson H, Pearlman D, Rachelefsky, G, Ratner P, Repsher L, Segal AT, Selner, JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. *Respiratory Medicine* 1999;93:603-12
120. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 1999; 160:1816-1823
121. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA, Comparison of inhaled Salmeterol and Oral Zafirlukast in patients with asthma. *J. Allergy Clin Immunol* 1999;103:1075-80
122. Routes JM, Nelson HS, Noda JA, Simon FT. Lack of correlation between Chlamydia pneumoniae antibody titers and adult-onset asthma. *J Allergy Clin Immunol* 2000; 105:391
123. Nelson HS, Kane RE, Petillo J; Banerji D; the Azmacort HFA Study Group. Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. *J Asthma*, 2000;37(2), 145-152 .
124. Nelson HS, Reynolds R, Mason J. Fexofenadine NCI is safe and effective for treatment of chronic idiopathic urticaria. *Ann Allergy Asthma Immunol* 2000; 84:517-522
125. Nelson HS, The use of standardized extracts in allergen immunotherapy. *J Allergy Clin Immunol* 2000; 106:41-5
126. Ross, RN, Nelson, HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: A meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. *Clin Therapeutics*, Vol 22, No. 3, 2000

127. Ross, RN, Nelson, HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: An analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Therapeutics, Vol 22, No. 3, 2000
128. Ross, RN, Nelson, HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of *Hymenoptera* venom hypersensitivity. Clin Therapeutics, Vol 22, No. 3, 2000
129. Katial RK, Reisner C, Buchmeier A, Bartelson BB, Nelson HS. Comparison of three commercial ultrasonic nebulizers. Ann Allergy Asthma Immunol 2000; 84:255-261
130. Yunginger J, Ahlstedt S, Eggleston P, Homburger HA, Nelson HS, Ownby DR, et al. Quantitative IgE antibody assays in allergic diseases. J Allergy Clin Immunol 2000;105:1077-84.
131. Nelson HS, Busse Wm, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. Journal Allergy Clin Immunology, 2000;106:1088-1095
132. Meiser JB, Nelson HS. Comparing conventional and acetone-precipitated dog allergen extract skin testing. J Allergy Clin Immunol 2001;107:744-5
133. Reisner C, Katial RK, Bartelson BB, Buchmeier A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001; 86:566-74
134. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-70.
135. Nelson HS. Combination therapy of bronchial asthma. Allergy and Asthma Proc 2001; 22:217-220.
136. Nelson HS. Future advances of immunotherapy. Allergy and Asthma Proc 2001; 22:203-207.
137. Calhoun, WJ, Nelson, HS, Nathan, RA, Pepsin, PJ, Kalberg, C, Emmett, A, Rickard, K, Dobinsky, P. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta2-agonists alone. Am J Respir Crit Care Med 2001; 614:759-763.
138. Comparison of inhaled Salmeterol and Oral Zafirlukast in Asthmatic Patients Using Concomitant inhaled Corticosteroids. Nelson HS, MD; Nathan, RA MD; Kalberg C, PhD; Yancey S. MS; Rickard, KA, MD <http://www.medscape.com/Medscape/GeneralMedicine/journal/2001/v03.n04/mgm0705.01.nels/mgm0705.01.nels-01.html>
139. Klinnert, M D, Nelson, H S, Price, M R, Adinoff, A D, Leung, D Y M, Mrazek, D A, Onset and persistence of childhood asthma: Predictors from infancy. Pediatrics 2001;108:995-996. electronic abstracts, <http://www.pediatrics.org> e69-e70
140. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001;87:379-385.
141. Corren J, Nelson H, Greos LS, Bensch G, Goldstein M, Wu J, Wang S, Newman K. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extra fine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001;87:405-411.
142. Casale TB, Nelson HS, Corren J, Newman K. Long-term safety of flunisolide hydrofluoroalkane metered-dose inhaler in adults and adolescents with asthma. Clin Drug Invest 2001;21(11):755-764.
143. Nelson HS, Stricker W, Casale TB, Raff H, Fourre JA, Aron DC, Newman KB. A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol 2002;42:1-8.

144. Roy SR, Nelson HS. A 47-year-old woman with progressive dyspnea and cough. *Ann Allergy Asthma Immunol* 2002;88:364-369.
145. Chervinsky P, Nelson HS, Bernstein DL, Berkowitz RA, Siegel SC. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. *Int J Clin Pract* 2002;56:19-25.
146. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokine sin nasal secretions after nasal antigen challenge: Lack of influence of antihistamines. *Ann Allergy Asthma Immunol* 2002;88:457-462.
147. Dreskin SC, Date SN, Foster SM, Martin D, Buchmeier A, Nelson HS. Measurement of changes in mRNA for IL-5 in noninvasive scrapings of nasal epithelium taken from patients undergoing nasal allergen challenge. *J Immunol methods* 2002;268:189-95.
148. Ewbank PA, Murray j, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. *J Allergy Clin Immunol* 2003;111:155-61.
149. Anand MA, Nelson HS Dreskin SC. A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria. *J Allergy Clin Immunol* 2003;111:1133-6
150. Casale TB, Nelson HS, Kemp J, Parasuraman B, Uryniak T, liljas B. Budesonide turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma. *Ann Allergy Asthma Immunol* 2003;90:323-330.
151. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. *J Allergy Clin Immunol* 2003;112:29-36.
152. Wyrwich KW, Nelson HS, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel report. *Ann Allergy Asthma Immunol* 2003;91:148-153.
153. Nelson HS, Wolfe JD, Gross G, Greos LS, Baitinger L, Scott C, Dorinsky P. Efficacy and safety of fluticasone propionate 44 µg/salmeterol 21 µg administered in a Hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. *Ann Allergy Asthma Immunol* 2003;91:263-9.
154. Nelson HS, Kolehmainen C, Lahr J, Murphy J, Buchmeier A. A comparison of multiheaded devices for allergy skin testing. *JACI* 2004;113:1218-9.
155. Dumouchel W, Smith ET, Beasley R, Nelson H, Yang X, Fram D, Almenoff JS. Association of asthma therapy and Churg-Strauss Syndrome: An analysis of postmarketing surveillance data. *Clin Therapeut* 2004;26:1092-1104.
156. Welch MJ, Nelson HS, Shapiro GA, Bensch GW, Sokol WN, Smith JA, Parasuraman BM. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers. *J Aerosol med* 2004;17:129-39
157. RD O'Connor, HS Nelson, R Borker, A Emmett, P Jhingran, K Rickard, P Dorinsky. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. *Pharmacoeconomics* 2004;22:815-825.
158. Pleskow WW, Nelson HS, Schaefer k, Claus R, Roach JM. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma *Allergy Asthma Proc* 2004;25:429-36
159. Nanda A, O'Connor M, Anand M, Dreskin SC, Zhang L, Hines B, Lane D, Wheat W, Routes JM, Sawyer R, Rosenwasser LJ, Nelson HS. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. *J Allergy Clin Immunol* 2004;114:1339-44.

160. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma *J Asthma* 2005;42:257-63.
161. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelsons HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. *Chest* 2005;128:1910-20.
162. Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. *Ann Allergy Asthma Immunol* 2006;96:19-23.
163. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129:15-26.
164. Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS. Effects of Esomeprazole 40 mg twice daily on asthma: A randomized placebo-controlled trial. *Am J Respir Crit Care Med* 2006;173:1091-7
165. Guyer BJ, Shimamoto SR, Bradhurst AL, Grossbard EB, Dreskin SC, Nelson HS. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms or nasal volumes in a nasal challenge model of allergic rhinitis. *Allergy Asthma Proc* 2006;27:208-13.
166. Lent AM, Harbeck R, Strand M, Sills M, Schmidt K, Efaw B, Lebo T, Nelson HS. Immunologic response to administration of standardized dog allergen extract at differing doses. *J Allergy Clin Immunol* 2006;115:1249-56.
167. Calverley PMA, Rennard S, Nelson HS, Karpel J, Abbate E, Staudinger H. One year treatment with mometasone furoate in patients with chronic obstructive pulmonary disease. *Respiratory Research* 2008; 9:73
168. Naclerio RM, Hadley JA, Stoloff S, Nelson HS. Patient and physician perspectives on the attributes of nasal allergy medications. *Allergy Asthma Proc* 2007;28:S11-S17.
169. Wingertzahn MA, Derebery MJ, Nelson HS. Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis. *Allergy Asthma Proc* 2007;28:S18-S24.
170. Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, Walton-Bowen K, LaVallee N, Stepanians M. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. *Ann Allergy Asthma Immunol* 2007;99:178-84.
171. Nelson HS, Gross NJ, Levine B, Rinehart M, Denis-Mize K. Cardiovascular safety of nebulized formoterol: Results of a placebo-controlled, double-blind phase III trial. *Clin Therapeutics* 2007;29:2167-78.
172. Gross NJ, Nelson HS, Lapidus RJ, Rinehart M, Denis-Mize K. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. *Respir Med* 2008;102:189-97.
173. Sharma S, Litonjua AA, Tantisira KG, Fuhlbrigge AL, Szeffler SJ, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST. Childhood Asthma Management Program Research Group. Clinical predictors and outcome of consistent bronchodilator response in the childhood asthma management program. *J Allergy Clin Immunol* 2008;122:921-8.
174. Kelly Hw, Van Natta ML, Covar RA, Tenascia J, Green RP, Strunk RC, CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. *Pediatric* 2008;122:e53-61.
175. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Salmeterol and inhaled corticosteroids on serious asthma –related events: A meta-Analysis. *Ann Intern Med* 2008;149:33-42

176. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. Budesonide and formoterol in one pressurized metered-dose inhaler improves patient-reported outcomes and asthma control variables in adults with mild to moderate persistent asthma. *Curr Med Res Opin* 2008;24:879-94
177. McDermott RA, Nelson HS, Dreskin SC. Mediator measurements after daily instillation of allergen: Increased IL-5 and decreased IFN-gamma. *Allergy Asthma Rev* 2008;29:146-51.
178. Strunk RC, Sternberg AL, Szeffler SJ, Zeiger RS, Bender B, Tonascia J. Childhood Asthma Management Program (CAMP) Research Group. Long-term budesonide or nedocromil treatment once discontinued does not alter the course of mild to moderate asthma in children and adolescents. *J Pediatr*. 2009;154:682-7.
179. Canonica GW, Busquet J, Casale T, Lickey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. *Allergy* 2009;64 Suppl 91:1-59.1
180. Nelson HS, Busse WW, Sanger M, Cutler G, Chipman JJ. Somatropin inhalation powder is safe in methacholine-sensitive patients with mild-to-moderate asthma. *Allergy, Asthma Proc* 2009;30:325-32.
181. Busse WW, Israel E, Nelson HS, Baker JW, Lisberg EE, Charous BL, Young DY, Vexler V, Shames RS. Daclizumab improves asthma control in patients with moderate-to-severe persistent asthma. *Am J Respir Crit Care Med* 2008;178:1002-8.
182. Brehm JM, Schuemann B, fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program Study. *J Allergy Clin Immunol* 2010;126:52-8.
183. Hanania NA, Donahue J, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol in COPD. *COPD*. 2010;7:17-31.
184. Sheila M. Amar, MD, Ronald J. Harbeck, PhD, Michael Sills, BS, Lori J. Silveira, MS, Holly O'Brien, RN, Harold S. Nelson, MD Response to Sublingual Immunotherapy with Grass Pollen Extract: Monotherapy versus Combination in a Multiallergen Extract *J Allergy Clin Immunol* 2009;124:150-6
185. Nelson HS, Gallegos CM, Silveira LJ, Newell JD, Gelfand EW. Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. *Allergy, Asthma Proc* 2009;30:284-92.
186. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, et al. B2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. *Am J Respir Crit Care Med* 2010;181:676-87.
187. Nelson HS, Bonuccelli C, Radner F, Ottosson A, Carroll K, Andersson T, LaForce C. Safety of formoterol in asthma patients: Combined analysis of data from double-blind, randomized controlled trials. *J Allergy Clin Immunol JACI* 2010;125:390-6
188. Massanari M, Nelson HS, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. *JACI* 2010;125:383-9
189. Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. *Thorax* 2010;65:132-8.
190. Healy B, Bibby S, Steele R, Weatherall M, Nelson H, Beasley R. Zileuton therapy and the Churg Strauss Syndrome: A review of the FDA AERS Database. (Submitted).
191. Krishnan JA, Bender BG, Wamboldt FS, Szeffler SJ, Adkinson NF Jr, Zeiger RS, et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. *J Allergy Clin Immunol* 2012;129:112-8.

192. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS et al. Effect of inhaled glucocorticoids in childhood on adult height. *N Engl J Med* 2012;367:904-12.
193. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. *J Allergy Clin Immunol* 2011;127:72-80.
194. ST Holgate, M Noonan, P Chanez, W Busse, I Dupont, I Pavord, A Hakulinen, L Paolozzi, J Wajdula, C Zang, H Nelson, D Raible. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of etanercept in subject the moderate to severe persistent asthma. *Eur Respir J* 2011;37:1352-9.
195. B Healy, S Bibby, R Steele, M Weatherall, H Nelson, R Beasley. Antineutrophil cytoplasmic auto-antibodies (ANCA) and myeloperoxidase (MPO) auto-antibodies in the clinical expression of Churg-Strauss Syndrome. *J Allergy Clin Immunology* 2012; (e-published 23 August 2012)
196. Hebert J, Nolte H, Maloney J, Blaiss M, Nelson HS. Efficacy of timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC). *Allergy Asthma Clin Immunol* 2011;7 (Suppl 2:A17) (Epub ahead of print)
197. Meltzer EO, Blaiss MS, Naclerio RM, Stoloff SW, Derebery J, Nelson HS, Boyle JM, Wingertzahn MA. Burden of allergic rhinitis: *Allergies in America, Latin America, and Asia-Pacific* adult surveys. *Allergy Asthma Proc* 2012;33:S113-S141.
198. Nelson H, Blaiss M, Nolte H, Würtz SO, Andersen JS, Durham S. Efficacy and Safety of the SQ-standardised grass allergy immunotherapy tablet in mono- and polysensitised subjects. *Allergy* 2013;68:252-5
199. Nelson HS, Lopez P, Curran-Everett D. Evaluation of a skin test device designed to be less painful. *J Allergy Clin Immunol* 2012;130:1422-3
200. Beasley R, Donohue JF, Kemp JP, Mehta R, Nelson HS, Clay M, Moton A, Kim H-J, Hederer B. Effect of Once-Daily Indacaterol Maleate/Mometasone Furoate on Exacerbation Risk in Adult Asthma. *BMJ Open* 2015;5:e006131
201. Maloney J, Bernstein DI, Nelson H, Creticos P, Herbert J, Noonan M, Skoner D, Zhou Y, Kaur AM Nolte H. Efficacy and safety of grass allergy immunotherapy tablets (AIT) treatment in a large randomized controlled trial in North American children and adults. *Annals Allergy, Asthma, Immunology* 2014;112:146-153.
202. Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z, Andersen JS. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. *Allergy* 2014;69:617-233.
203. Nelson HS, Lopez P, Curran-Everett D. Pain-perception and performance of 3 devices for single-site allergen skin testing. *Allergy, Asthma Proc.* 2014;35:63-5.
204. Demoly P, Casale T, Nelson H, Calderon M. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. *J Allergy Clin Immunol* 2013;132:1322-36.
205. Nelson H, Lehmann L, Blaiss MS. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergen tablet. *Curr Med Res Opin* 2013;28:1043-51.
206. Hebert J, Blaiss M, Wasserman S, Kim H, Creticos P, Maloney J, Kaur A, Nelson H, Nolte H. The efficacy and safety of the timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. *Allergy, Asthma Clin Immunol* 2014;10:53
207. Kim H, Wasserman S, Hebert J, Blaiss M, Nelson H, Creticos P, Kaur A, Maloney J, Li Z, Nolte H. Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis. *Allergy, Asthma, Clin Immunol* 2014;10: 55

208. [Nelson H](#), Carter S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. *J Allergy Clin Immunol Pract* 2015;3:256-66.
209. Nolte H, Maloney J, [Nelson HS](#), Bernstein DI, Lu S, Li Z, Kaur A, Lemell P, Zieglmayer P, Zieglmayer R, Horak F. Dose-related efficacy and onset of action of house dust mite sublingual immunotherapy tablet in an environmental exposure chamber. *J Allergy Clin Immunol* 2015;135:1494-1501.
210. Maloney J, Berman G, Gagnon R, Bernstein DI, [Nelson HS](#), Kleine-Tebbe J, Kaur A, Li Q, Nolte H. Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerate. *J Allergy Clin Immunol Pract* 2016;4:301-9, e302.
211. Christensen LH, Ipsen H, Nolte H, Maloney J, [Nelson HS](#), Weber R, Lund K. Short ragweed is highly cross-reactive with other ragweeds. *Ann Allergy Asthma Immunol* 2015;115:490-5.
212. Nolte H, Bernstein I, [Nelson HS](#), Kleine-Tebbe J, Sussman GL Seitzberg D, Rehm D, et al. Efficacy and safety of the SQ house dust mite SLIT-tablet in North American adolescents and adults with mite allergy. *J Allergy Clin Immunol* 2016;138:1631-8.
213. Durham S, Creticos PS, [Nelson HS](#), Li Z, Kaur A, Meltzer EO, Nolte H. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. *Journal Allergy Clin Immunol* 2016;138:1081-1088.
214. Zieglmayer P, Nolte H, [Nelson HS](#), Bernstein DI, Kaur A, Jacobi H, Lemell P, Schmutz R, Zieglmayer R, Forak F. SQ House Dust Mite Sublingual Immunotherapy Tablet Long-term effects in an environmental exposure chamber trial. *Ann Allergy Asthma Immunol* 2016;117:690-696.
215. Nolte H, Casale TB, Lockey R, Fogh BS, Kaur A, Lu S, [Nelson HS](#). Epinephrine use in clinical trials of sublingual immunotherapy tablets. *J Allergy Clin Immunol Pract* 2017;5:84-89
216. Maatsuoka T, Bernstein DI, Masuyama K, Nolte H, Okamiya K, Seitzberg D, [Nelson HS](#). Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. *Ped Allergy Immunol* 2017;28:661-667.
217. Nolte H, Bernstein DI, Sussman GL, Svanholm F, Lu S, Husoy B Fogh BS, [Nelson HS](#). Impact of adverse event solicitation on the safety profile of SQ house dust mite sublingual immunotherapy tablet. *JACI Pract* 2018 Epub ahead of print
218. Lehrer PM, Irvin C, Lu S-E, Scardella A, Roehmheld-Hamm B, Aviles-Velez, MI, Graves J, Vaschilol EG, Vaschilol B, Hoyte F, [Nelson H](#), Wamboldt F. Heart rate variability biofeedback does not substitute for asthma steroid controller medication. *App Psychophysiol Biofeedback* 2018;43:57-73
219. Nolte H, Bernstein D, Kleine-Tebbe J, Fejerskov P, Li Q, Lu S, [Nelson H](#). Treatment with the SQ HDM SLIT-tablet may be initiated year-round. *JACI Pract* 2018; 6:1758-1760.
220. Bernstein DI, Kleine-Tebbe J, [Nelson HS](#), Bardelas JA, Jr, Sussman GL, Lu S, Rehm D, Fogh BS, Nolte H. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. *Ann Allergy Asthma Immunol* 2018;121:105-110.
221. Nolte H, Bernstein DI, [Nelson HS](#), Ellis AK, Kleine-Tebbe J, Lu S. Efficacy and safety of ragweed SLIT-tablet in children with allergic rhinoconjunctivitis in a randomized, placebo-controlled trial. *J Allergy Clin Immunol Pract* 2020;8:2322-2331.
222. Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, et al. Combination treatment with tezepelumab and allergen immunotherapy promotes tolerance to nasal allergen challenge: a randomized control trial. *J Allergy Clin Immunol* 2023;151:192-201.

223. Nelson HS, Bernstein DI, Biedermann T, Nolte H. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis. *Allergy Asthma Proc* 2024;45:33-36.

Reviews

1. Nelson HS: The beta adrenergic theory of bronchial asthma. *Pediatric Clin North Am* 1975;22:53.
2. Nelson HS: Allergic reactions to drugs. *Advances in Asthma and Allergy*. Vol. 3, No. 2:18;1976.
3. Nelson HS: Special problems in drug allergy. *Advances in Asthma and Allergy*. Vol. 4, No. 1:22;1977.
4. Nelson HS: The selection of atopic allergens. *J Asthma* 1981;18:23.
5. Nelson HS: Getting the most out of beta-adrenergics today. *J Respir Dis* 1982;3:11.
6. Nelson HS: Beta adrenergic agonists. *Chest* 82(suppl):33s;1982.
7. Nelson HS: The clinical relevance of IgE. *Ann Allergy* 1982;49:73.
8. Nelson HS: Diagnostic procedures in allergy. I. Allergy skin testing. *Ann Allergy* 1983;51:411.
9. Nelson HS: Diagnostic procedures in allergy. II. Bronchial provocation testing. *Ann Allergy* 1983;51:488.
10. Nelson HS: Gastroesophageal reflux and pulmonary disease. *J Allergy Clin Immunol* 1984;73:546.
11. Nelson HS: What is atopy? Sidestepping semantics. *Postgrad Med* 1984;76:118.
12. Nelson HS: Stepwise therapy of bronchial asthma: The role of beta-adrenergic agonists. *Ann Allergy* 1985;54:289.
13. Weber RW, Nelson HS: Pollen allergens and their interrelationships. *Clin Rev* 6 Allergy 1985;3:291.
14. Nelson HS. The atopic diseases. *Ann Allergy* 1985;55:441.
15. Weber RW, Nelson HS. Immunologic and atopic aspects of pregnancy and lactation. *An allergy* 1986;57:159-66.
16. Nelson HS: The current status of therapy with beta-adrenergic bronchodilators. *Schumpert Medical Quarterly* 1986;4:281.
17. Nelson HS: Adrenergic therapy of bronchial asthma. *J Allergy Clin Immunol* 1986;77:771.
18. Nelson HS: Adrenergics in asthma: Where we stand today. *J Respir Dis* 1986;7:43.
19. Nelson HS: Gastroesophageal reflux and bronchial asthma. *Airway Diseases* 3:2(2); 1987.
20. Nelson HS: Bronchodilator therapy for reversible obstructive airway disease. *J Respir Dis* 1989: Oct (Suppl); s58.
21. Volz MA, Nelson HS: Drug allergy: Best diagnostic and treatment approaches. *Post Graduate Medicine* 1990;87(5);137-149.
22. Nelson HS: Is gastroesophageal reflux worsening your patient's asthma? *J. Respir. Dis.* 1990;11:827-844
23. Cross D, Nelson HS. The role of the peak flow meter in the diagnosis and management of asthma. *J Allergy Clin Immunol* 1991;87:120-8.

24. Nelson HS: Allergic rhinitis: Diagnosis and mechanisms. *J Respir Dis* 1991;12:s16-s18.
25. Nelson HS: The Natural History of Asthma. *Ann Allergy* 1991;66:196-203.
26. Nelson HS: Literature Review 1991 for ABAI Exam. Antigens and Allergens. *Annals of Allergy*, 1991;67:171-173.
27. Nelson HS: B-Adrenergic Agonist: Optimal use in acute asthma, alone and in combination with other bronchodilators. *Consultant* 1993;33:29-33.
28. Nelson HS: Issues in allergen extract mixes. *Allergy Proc* 1993;14:391-3
29. Nelson HS. Variables in allergy skin testing. *Allergy Proc* 1994;15(6):265-268.
30. Nelson HS. β -Adrenergic Bronchodilators. *New Engl J Med* 1995;333(8):499-506.
31. Tilles SA, Nelson HS. Long-acting beta agonist. *J Asthma* 1995;32(6):397-404.
32. Nelson HS: New developments in bronchodilator therapy. *Current Opinion in Pulmonary Medicine* 1996;2:35-39.
33. Tilles SA, Nelson HS. Differential diagnosis of adult asthma. *Immunol & Allergy Clin of N America* 1996;16(1):19-34.
34. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal corticosteroid for allergic rhinitis. *Clin Therapeutics* 1997;19(1):1-20.
35. Nelson HS. Immunotherapy with foods. *International J Immuno Pathology and Pharmacology* 1997;10:77-9.
36. Nelson HS. Does allergen Immunotherapy have a role in the treatment of bronchial asthma? *Allergy and Asthma Proc* 18:157-162, 1997.
37. Tilles, SA, Nelson HS. New onset asthma in the elderly. In: *Immunology and Allergy Clinics of North America: Treatment of Asthma and Allergic Disease in the Elderly*. 1997;17(4):575-586. Montanardo A, Bardana, Jr., Eds.
38. Szeffler SJ, Nelson HS. Agents for anti-inflammatory treatment of asthma. *J. Allergy Clin. Immunol* 1998;102:523-535.
39. Nelson HS. Role of inhaled glucocorticoids in asthma. *Immunol Allergy Clin North America* 1999;19:739-751
40. Nelson HS. Clinical experience with levalbuterol. *J Allergy Clin Immunol* 1999;104:S77-84.
41. Nelson HS. The importance of allergens in the development of asthma and the persistence of symptoms. *J Allergy Clin Immunol* 2000; 105:S628-632
42. Nelson HS, Part 1. The Importance of Allergens in the Development of Asthma and the Persistence of Symptoms. *Disease-a-Month* 2001: 47:5-15
43. Nelson HS. Future advances of immunotherapy. *Allergy Astham Proc* 2001;22:203-7.
44. Nelson HS. Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. *J Allergy Clin Immunol* 2001;107:398-416.
45. Nelson HS. Variables in allergy skin testing. *Immunol, Allergy Clinics North America* 2001;21:281-90

46. Nelson HS Advances in upper airway diseases and allergen immunotherapy J Allergy Clin Immunol 2003;111:S793
47. Nelson HS Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003;112:S96-100.
48. Nelson HS Preparing and mixing allergen vaccines. Clin allergy Immunol 2004;18:457-79.
49. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2004;113:635-42.
50. Nelson, HS Combination therapy of long-acting B agonists and inhaled corticosteroids in the management of chronic asthma. Curr Allergy, Asthma reports 2005;5:123-9
51. Nelson HS Advances in Upper Airway Diseases and Allergen Immunotherapy. J Allergy Clin Immunology 2005;115:676-84.
52. Nelson HS. Is there a problem with inhaled long-acting β -adrenergic agonists? J Allergy Clin Immunol 2006;117:3-17
53. Oppenheimer J, Nelson HS skin testing. Ann Allergy Asthma Immunol 2006;96, Number 2, Suppl 1 S6-S12
54. Nelson HS. Efficacy and safety of allergen immunotherapy in children. Ann Allergy Asthma Immunol 2006;96, Number 2 Suppl 1 pages S2-S5.
55. Nelson HS Advances in Upper Airway Diseases and Allergen Immunotherapy. J Allergy Clin Immunology 2006;117:1047-53
56. AAAAI/ACAAI Task Force Report: Sublingual immunotherapy – A comprehensive review. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. J Allergy Clin Immunol 2006;117:1021-35.
57. Nelson HS. Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe. Primary Care Respiratory Journal 2006;15:271-7
58. Nelson HS. Innovations in Allergen Immunotherapy. *Respiratory Digest*. 2006; 8(3):3-13
59. Nelson HS. Allergen immunotherapy: Where is it now? J Allergy Clin Immunol 2007;119 (4):769-79.
60. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007;119 (4):
61. JP. Karpel, MD, and HS Nelson, MD
Mometasone Furoate Dry Powder Inhaler: a Once Daily Inhaled Corticosteroid for the Treatment of Persistent Asthma. Cur Med Res Opin 2007;23:2897-2911.
62. Oppenheimer J, Nelson HS. Safety of long-acting b-agonists in asthma: a review. Curr Opinion in Pulm Med 2008;14:64-9.
63. Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009;123:763-9.
64. Nelson HS, Nathan R, Carr W, Portnoy J. Update on the Safety of Long-acting Beta-agonists in Combination with Inhaled Corticosteroids. Ann Allergy Asthma Immunol 2009;102:11-15
65. Nelson HS. Specific immunotherapy with allergen mixes; what is the evidence? Current Opinion in allergy and clinical Immunology 2009;9:549-53

66. Nelson HS. Subcutaneous Immunotherapy for Optimal Effectiveness. Immunology and Allergy Clinics of North America 2011;31:211-26.
67. Nelson HS. Some highlights of the first century of immunotherapy. Ann Allergy Asthma Immunol 2011;107:417-21.
68. Nelson HS. History of Specific Immunotherapy. Allergen Products for Diagnosis and Therapy: Regulation and Science. 13th International Paul-Ehrlich Seminar. September 14-17, 2011. Page 3-5. Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen. 97:3-5,2013.
69. Nelson H, Lehmann L, Blaiss MS. Brief Report: Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet. Curr Med Res Opin 2012;28:1043-51.
70. Nelson HS. What will allergen immunotherapy look like in the future? Annals Allergy Asthma Immunol 2012;109:87-9
71. Nelson HS. Sublingual immunotherapy: the US experience. Curr Opinion Allergy Clin Immunol 2013;13:663-8.
72. Nelson HS. SCIT versus SLIT: Which is more effective? J Allergy Clin Immunol in Practice 2014;2:144-9.
73. Nelson HS. Sublingual immunotherapy for aeroallergens: Optimal patient dosing, regimen and duration. Curr Treatment Options in Allergy 2014;1:79-90.
74. Nelson HS. New forms of allergy immunotherapy for rhinitis and asthma. Allergy Asthma Proc 2014;35:271-7.
75. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? Curr Opin Allergy Clin Immunol 2014;14:542-8
76. Nelson HS. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Rev Clin Immunol 2014;10:137-51.
77. Nelson HS. Allergen immunotherapy: what's new, what's next? Expert Review of Clinical Immunology 2015;11:959-61.
78. Nelson HS, Makatsori M, Calderon MA. SCIT and SLIT: comparative efficacy, current and potential indications and warning – US vs. Europe. Immunology and Allergy Clinics 2016;36:13-24.
79. Dahl R, Roberts G, de Blic J, Canonica GW, Killeine-Tebbe J, Nolte H, Lawton S, Nelson HS. SQ grass sublingual allergen immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy, Asthma Proc 2016;37:92-104..
80. Nelson HS Allergen immunotherapy for the multiple pollen sensitive patient. Expert Review of Clinical pharmacology. 2016;6:1-9.
81. Nelson HS. Allergen immunotherapy (AIT) now and in the future. Allergy, Asthma Proc 2016;37:268-272.
82. Nelson HS. Inhalation devices, delivery systems, and patient technique. Ann Allergy Asthma Immunol 2016;117:606-612
83. Nelson HS, Durham SR. Allergen immunotherapy for a teenager with seasonal allergic rhinitis due to grass pollen: subcutaneous or sublingual route? J Allergy Clin Immunol Pract 2017;5:52-57.

84. Brunton S, Nelson HS, Bernstein DI, Lawton S, Lu S, Nolte H. Sublingual immunotherapy tablets as a disease-modifying, add on treatment option to pharmacotherapy for allergic rhinitis and asthma. *Postgraduate Medicine* 2017;129:581-589
85. Nelson HS. Immunotherapy coming of age: Notable Advances during the First Hundred Years. *Expert Review of Clinical Immunology* 2017;13:389-392
86. Nelson HS. Current and Future challenges of SCIT and SLIT for US allergists. *Ann Allergy Asthma Immunol* 2018;121:278-280
87. Nelson HS. Ragweed allergy immunotherapy tablet MK-3641 for treatment of allergic rhinitis. *Exp Review Clin Immunol* 2018;14:1003-1011
88. Nelson HS. Immunotherapy for house-dust mite allergy. *Allergy Asthma Proc* 2018;39:264-272.
89. Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F-1000 Research (23 August 2018)
90. Nelson HS. Allergy Immunotherapy: Strategies to minimize adverse reactions. *Allergy, Asthma Proc.* 2020;41:38-44.
91. Nelson HS. Allergy Immunotherapy: Strategies to improve efficacy. *Allergy Asthma Proc.* 2020;41:26-37.
92. Nelson HS. Allergy Immunotherapy (AIT): Future Directions for the 2020's. *Allergy Asthma Proc.* 2020 Sep 1;41(5):314-325.
93. Calderon MA, Wasserman S, Bernstein DI, Demoly P, Douglass J, Gagnon R, Katelaris CH, Kim H, Nelson HS, Okamoto Y, Okubo K, Virchow JC, DuBuske L, Casale TB, Canonica GW, Nolte H. *J Allergy Clin Immunol Pract* 2020;8:2920-2936.
94. Nelson HS. The Evolution of Allergy Immunotherapy. *Ann Allergy Asthma Immunol.* 2021;126:357-366.
95. Nelson HS. To Mix or Not to Mix in allergy immunotherapy vaccines. *Curr Opin Allergy Clin Immunol.* 2021;21:583-9.
96. Nelson HS. How important is proper dosing for subcutaneous and sublingual allergy immunotherapy? *Allergy, Asthma Proceedings.* 2021;42:368-377.
97. Nelson HS. How our treatment of asthma has changed in the last half century. *Ann Allergy Asthma Immunol* 2021;127:518-9.
98. Nelson HS. The evolution of allergy immunotherapy. *An Allergy Asthma Immunol* 2021;126:357-366.
99. Nelson HS. Allergy immunotherapy: Future directions for the 2020's. *Allergy Asthma Proc* 2020;41:314-325
100. Nelson HS. Future directions in AIT. *Allergy Asthma Proc* 2022;43:356-361.
101. Nelson HS. Standardized allergen extracts. *Allergy Asthma Proc* 2022;43:327-332.
102. Nelson HS. Return of the mixed bacterial vaccine. *Allergy Asthma Proc* 2022;43:501-508.
103. Nelson HS. Allergy immunotherapy of allergic fungal respiratory diseases. *Allergy, Asthma Proc* 2023;44:395-401.

104. Nelson HS. Allergy Immunotherapy: State of the Art. Current Treatment Options in Allergy 2023;10:166-183

105. Nelson HS. The Art of Immunotherapy. J Allergy Clin Immunol Pract. 2024;12:1-10 :Epub 2023 Oct 28 PMID 37898175.

106. Nelson HS. Sowers T, Plunkett G, Nolte H, Rance K. The art of dosing for subcutaneous immunotherapy in North America. J allergy clin Immunol Pract 2024;12:13-22.. Epub 2023 June 28 PMID 37385447.

Book Chapters

1. Nelson HS. Adverse reactions to drugs: Hypersensitivity. In: Current Therapy. Conn HF, ed. Philadelphia, PA: W. B. Saunders, 1979.
2. Nelson HS. Allergens, Antigenic Makeup. In: Textbook of Clinical Allergy. Lockey R, Ed. Med Exam Publishing Co. 1979.
3. Nelson HS. Pregnancy and Allergic Diseases. Chapter 51 in: Allergic Diseases of Infancy, Childhood and Adolescence. Bierman CW, Pearlman DS, eds. Philadelphia, PA: W.B. Saunders Company, 1980.
4. Weber RW, Nelson HS. Immunologic aspects of lactation in pregnancy. Ann Allergy 1986;57:159.
5. Nelson HS, Weber RW. Endocrine aspects of allergic diseases. Chapter 15 in: Allergic Diseases from Infancy to Adulthood, 2nd Edition. Bierman CW, Pearlman DS, Eds. Philadelphia, PA: W. B. Saunders, 1988.
6. Nelson HS. Allergic Rhinitis. In: Current Therapy in Allergy, Immunology and Rheumatology - 3. Lichtenstein LM, Fauci AS, eds. Philadelphia, PA: B.C. Decker, p. 1, 1988.
7. Nelson HS. Adrenergic Agents II. Beta-adrenergic therapy. Chapter 29 in: Allergy: Principles and Practice, 3rd Edition. Middleton EW, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, eds. St. Louis, MO: C. V. Mosby, 1988.
8. Nelson HS. Clinical application of immediate skin testing. Chapter 22 in: Provocative Challenge Procedures: Background and Methodology. Spector SL, ed. Mt. Kisco, NY: Futura Publishing Company, Inc., 1989.
9. Nelson HS. Chronic rhinitis: Diagnosis and management. In: Practical Care of the Ambulatory Patient. Stults BM, Dere WH, eds. Philadelphia, PA: W.B. Saunders Company, pp. 323-33, 1989.
10. Nelson HS. Beta adrenergic therapy. Chapter 31 Adrenergic Agents in: Allergy Principles and Practice. Middleton Jr E, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, Busse WW, eds. St. Louis, MO: Mosby-Yearbook, Inc., pp. 785-807, 1993.
11. Nelson HS. Chronic severe asthma. In: Bronchial Asthma Mechanisms and Therapeutics, 3rd Edition. Weiss EB, Stein M, eds. Boston, MA: Little Brown and Company, pp. 1054-1061, 1993.
12. Nelson HS. Allergic and nonallergic rhinitis. In: Current Therapy in Adult Medicine, 4th Edition. Kassirer JP, Greene HL, eds. St. Louis, MO: Mosby, pp. 1250-1254, 1994.
13. Nelson HS. Clinical application of immediate skin testing. Chapter 26 in: Provocation Testing in Clinical Practice. Spector SL, ed. New York: Marcel Dekker, Inc, pp. 703-727, 1995.
14. Nelson HS. Diagnosis and management of severe asthma in the adult. Szeffler SJ, Leung DYM, Editor-in-Chief. New York: Marcel Dekker, Inc., 1995.
15. Nelson HS. Allergic and nonallergic rhinitis. In: Current Therapy in Internal Medicine. Cassier JP, Editor-In-Chief. St. Louis, MO: Mosby Year Book Inc., 1996.

16. Nelson HS. Urticaria and angioedema. Chapter 23 in: *Dermatology Secrets*. Fitzpatrick JE, Aeling JL, eds. Hanley & Belfus, Inc., pp. 150-154, 1996.
17. Nelson HS. Beta Adrenergic agonists. Chapter 105 in: *Asthma*. Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, eds. Philadelphia, PA: Lippincott Raven, pp. 1507-21, 1997.
18. Green AG, Nelson HS. Adrenergic agents. Chapter 43 in: *Allergy Principles & Practice*, 5th Edition. Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. St. Louis, MO: Mosby-Yearbook, Inc., pp. 571-588, 1998.
19. Nelson HS. Asthma guidelines and outcomes. Chapter 64 in: *Allergy Principles & Practice*, 5th Edition. Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. St. Louis, MO: Mosby-Yearbook, Inc., pp. 927-37, 1998.
20. Nelson HS. Immunotherapy for inhalant allergens. Chapter 74 in: *Allergy Principles & Practice*, 5th Edition. Middleton Jr E, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, Busse WW, eds. St. Louis, MO: Mosby-Yearbook, Inc., pp. 1050-1062, 1998.
21. Nelson HS. Beta-Agonists. Chapter 29 in: *Allergy and Allergic Diseases: The New Mechanisms and Therapeutics*. Denburg JA, Ed. Totowa, NJ: Humana Press, pp. 541-557, 1998.
22. Nelson, HS. Preparing and mixing allergen vaccines. Chapter 22 in: *Allergens and Allergen Immunotherapy*, 2nd Edition, Revised and Expanded. New York: Marcel Dekker, pp. 401-422, 1999.
23. Nelson, HS. The role of allergy. Chapter 4 in: *Pediatric Asthma, Volume 126 Lung Biology in Health and Disease*. New York: Marcel Dekker, pp. 117-132, 1999.
24. Nelson HS. Recalcitrant asthma. Chapter 123 in: *Asthma & Rhinitis*, 2nd Edition. Busse & Holgate, eds. Oxford, UK: Blackwell Science, pp. 1864-1879, 2000.
25. Nelson HS, Handley DA, Morley J. New drugs for asthma, allergy and COPD. Single-Isomer β -Agonists, *Prog Respir Res*. Basel, Karger, pp. 64-67, 2001.
26. Nelson HS. Immunotherapy in the management of asthma. Chapter 7 in: *Asthma*. Slavin RG, Reisman RE, eds. Philadelphia, PA: American College of Physicians, pp. 105-117, 2002.
26. Tilles SA, Nelson HS. Asthma Diagnosis and Differential Diagnosis. Chapter 5 in *Current Review of Asthma* Ed MA Kaliner. Current Medicine, Inc, Philadelphia. 2002.
27. Nelson HS. In vivo testing for immunoglobulin E-mediated sensitivity. Chapter 23 in. *Pediatric Allergy: Principles and Practice*. Eds (Leung DYM, Sampson HA, Geha RS, Szeffler SJ) Mosby, St Louis, MO, USA 2003.
28. Nelson HS. Immunotherapy for inhalant allergens. Chapter 80 in: *Middleton's Allergy Principles & Practice*, 6th Edition. Eds Adkinson NF .Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER. Mosby Philadelphia . 2003
- 29 Nelson HS. Beta-Adrenergic Agonists. Chapter 49 in: *Middleton's Allergy Principles & Practice*, 6th Edition Eds: Adkinson NF .Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER Mosby Inc., Philadelphia 2003
30. Nelson HS Preparing and mixing allergen vaccines. Chapter 24 in *Allergens and Allergen Immunotherapy*, 3rd Ed. .Lockey RF, Bukantz SC, (Eds) Marcel Dekker, Inc. New York, Basel. 2004
31. Nelson HS Preparing and mixing allergen vaccines. Chapter 19 in *Allergens and Allergen Immunotherapy*, 4rd Ed. .Lockey RF, Ledford DK , Bousquet J (Eds) Informa Healthcare. New York, London, 2008

32. Nelson HS. *In Vivo* Testing for IgE Mediated Sensitivity. Chapter in. *Pediatric Allergy: Principles and Practice*. Eds (Leung DYM, Sampson HA, Geha RS, Szeffler SJ) Mosby, St Louis, MO, USA 2010.
33. Holgate ST, Canonica GW, Baena-Cagnani CG, Casale T, Zitt M, Nelson H, Vichyanond P. Chapter 2.2, Asthma, in *World Allergy Organization White Book on Allergy*. Eds. R Pawankar, GW Canonica, ST Holgate, RF Lockey. 2011. WAO Milwaukee, WI, USA.
34. Nelson HS. Immunotherapy for Inhalant Allergens. Chapter 6, in *Manual of Allergy and Immunology*, 5th Ed. Eds DC Adelman, TB Casale, J Corren. Lippincott, Williams & Wilkins. Philadelphia, PA. 2012.
35. Nelson HS. Allergen Immunotherapy. *Textbook of Allergy for the Clinician*. Eds., PK Vedanthan, HS Nelson, S Agashe, P Mahesh, R Katial. Science Publishers, New Hampshire 2014
36. Nelson HS. Pharmacotherapy. *Textbook of Allergy for the Clinician*. Eds. PK Vedanthan, HS Nelson S Agashe, P Mahesh, R Katial. Science Publishers, New Hampshire 2014
37. Nelson HS and Norman PS. Allergen Specific Immunotherapy in. *History of Allergy*, Eds Karl-Christian Bergman and Johannes Ring. *Chem Immunol Allergy*. 2014;100: 333-338.
38. Nelson HS. Introducing atopy. Chapter 16 in *Landmark Papers in Allergy*. Edited by Aziz Sheikh, TAE Platts-Mills, Allison Worth, and Stephen Holgate. Oxford University Press, Oxford, U.K. 2013
39. Nelson HS. Injection immunotherapy for inhalant allergens. Chapter 87 in *Middleton's Allergy: Principles and Practice*. 8th Ed. Authors: Adkinson, Bochner, Burks, Busse, Holgate, Lemanske and O'Hehir.
40. Holgate ST, Canonica GW, Baena-Cagnani CE, Casale TB, Zitt M, Nelson HS, Vichyanond P. Section 2.2 Asthma Chapter 34 in *World Allergy Organization White Book on Allergy*, 2nd. Eds Pawankar R, Canonica GW, Holgate ST, Lockey RF. 2013, WAO Milwaukee, WI, USA.
41. Nelson HS. PREPARING SUBCUTANEOUS ALLERGEN VACCINES. Chapter 22 *Allergens and Allergen Immunotherapy*. Fifth Edition. Richard F Lockey and Dennis K Ledford Editors. Taylor and Francis Group, CRC Press. Abingdon, Oxfordshire, UK. 2014.
42. Nelson HS In vivo testing for immunoglobulin E-mediated sensitivity. Chapter 19 in. *Pediatric Allergy: Principles and Practice*. 3rd Ed. DYM Leung, SJ Szeffler, FA Bonilla, CA Akdis, HA Sampson Eds. Elsevier 2016.
43. Nelson HS. Injection immunotherapy for inhalant allergens. In *Middleton's Allergy: Principles and Practice*. 9th Edition. 2019. Elsevier
44. Nelson HS. Breakthroughs in subcutaneous allergy immunotherapy. Chapter 12 in "Immunotherapy for allergic disease", 1st Edition. Ed L Cox. Elsevier, Inc, Amsterdam NE, Oxford UK, Cambridge MA, USA. 2020.
45. Nelson HS. Indications for and Preparing and Administering Subcutaneous Allergen Vaccines. Chapter 26, in *Allergens and Allergen Immunotherapy*, Sixth Edition. Ed RF Lockey and DK Ledford.
46. Nelson HS. *Allergen Immunotherapy*. *Textbook of Allergy for the Clinician* 2nd Ed.
47. Nelson HS. *Risk factors for allergies and asthma*. *Textbook of Allergy for the Clinician* 2nd Ed.
48. Goddard AG, Nelson HS, Katial R, Hoyte F. The Pharmacotherapy of Rhinitis and Asthma. Chapter 15. *Textbook of Allergy for the Clinician*, 2nd Ed.
49. Nelson HS. Allergy immunotherapy for inhalant allergens. Chapter 9 in *Diagnostic and therapeutic procedures in allergy*.

50. F Hoyte, C Kwait, Nelson H. Diagnosis of allergy and asthma. Chapter 3A in Diagnostic and Therapeutic Procedures in Allergy.

Books Edited.

1. Vadanathan PK, Nelson H, Agase SN, Mahesh PA, Katial R. Textbook of Allergy for the Clinician. CRC Press. Taylor & Francis Group Boca Raton, London, New York. 2014.

2. Textbook of Allergy for the Clinician 2nd Ed.

Miscellaneous

1. Nelson HS: Routine sinus roentgenograms and chronic urticaria. JAMA 1984;251:1680.
2. Sheffer AL, Bailey WC, Bleecker ER, Busse WW, Ellis EF, Evans D, Fanta CH, Janson-Bjerklie S, Malveaux FJ, Murphy SA, Nelson HS, Shapiro G: Guidelines for the diagnosis and management of asthma: National Heart, Lung and Blood Institute. National Asthma Education Program - Expert Panel Report. J Allergy Clin Immunol 1991;88:425-534.
3. Dogar JH, Nelson HS, Hamilos DL: Clinical Allergy-Immunology Rounds: A 33-year old Caucasian woman with asthma and emphysema . Ann All 1992;68:307-14.
4. Oppenheimer J, Nelson HS: Refractory exercise induce cough in a competitive high school athlete. MD Air Currents 1992;1:20-24.
5. Hamilos DL, Oppenheimer JJ, Nelson HS, et. al: Suggested approaches for research protocols involving the potential for life-threatening reactions. J. Allergy Clin Immunol. 1993;92:1101-1120.
6. Nelson HS: Quality Control in Skin Testing - Guest Editorial Ann Allergy 1993;71:3-4.
7. Luskin AT, Clark S, Frederiksen M, Jacobs M, Kaufman R, Myers D, Nelson HS, Schatz M, Scialli A, Wise RA: Report of the working group on asthma and pregnancy: executive summary: management of asthma during pregnancy. J Allergy Clin Immunol 1994;93:139-162.
8. Rosenwasser L, Borish L, Gelfand E, Leung D, Nelson H, Szeffler SJ. 1994 Yearbook of Allergy and Clinical Immunology. LJ Rosenwasser, Editor-in-Chief. Mosby-Year Book. St. Louis, Missouri 1994.
9. Rosenwasser L, Borish L, Gelfand E, Leung D, Nelson H, Szeffler SJ, . 1995 Yearbook of Allergy and Clinical Immunology. LJ Rosenwasser, Editor-in-Chief. Mosby-Year Book. St. Louis, Missouri 1995.
10. Hermanoff MH, Nelson HS. New onset dyspnea with reversible airway obstruction in a 70-year-old man. Ann Allergy 1995;75:475-480.
11. Nelson HS. Subsensitvity to the bronchodilator action of β_2 -adrenergic agonist. Letters to the Editor. Am J Med 1995;99:449-450.
12. Szeffler SJ, Nelson HS, Welch MJ. Safety and appropriate use of salmeterol in the treatment of asthma. Position Statement AAAAI Committee on Drugs. J Allergy Clin Immunol 1996;98:475-80.
13. Nelson HS. Asthma guide for patients. HIN, Inc. The Health Information Network. 1996.
14. Rosenwasser L, Borish L, Gelfand E, Leung D, Nelson H, Szeffler SJ. 1996 Yearbook of Allergy and Clinical Immunology. LJ Rosenwasser, Editor-in-Chief. Mosby-Year Book. St. Louis, Missouri 1996.
15. Achieving healthy indoor air. Report of the ATS Workshop, Santa Fe, New Mexico, November 16-19, 1995. JM Samet and the Workshop participants. Amer Respir Crit Care Medicine, 1997;156:S33-S64.

16. Nelson HS. Allergen and Irritant Control: Importance and Implementation Clinical Cornerstone Vol 1, No. 2, August-September, 1998, pp 57-66.
18. Nelson HS. Outpatient Management of Asthma. Primary Care Case Reviews, March 1998, Vol. 1, No. 1, pp 3-11.
19. Selner, JC, Sullivan, TJ, Ahlstedt S., Claman HN, Kolen, WK, Nelson, HS, Platts-Mills, TAE, Segall N, and Williams, PB. Current issues relating to in vitro testing for allergen-specific IgE: a workshop report. Ann Allergy Asthma Immunol 1999;82:407-412.
20. Nelson HS Levalbutamol A Viewpoint by Hal Nelson BioDrugs, June 1999, Vol 11, No 6, pp 367-444.
21. Rosenwasser L, Borish L, Gelfand E, Leung D, Nelson H, Szeffler SJ. 1997 Yearbook of Allergy and Clinical Immunology. LJ Rosenwasser, Editor-in-Chief. Mosby-Year Book. St. Louis, Missouri 1997.
22. Rosenwasser L, Boguniewicz M, Borish L, Nelson HS, Routes J, Spahn J. 1998 Yearbook of Allergy and Clinical Immunology. LJ Rosenwasser, Editor-in-Chief. Mosby-Year Book. St. Louis, Missouri 1998.
23. Nelson, HS, Urticaria and Angioedema, Dermatology Secrets in Color, Second Edition, 163-168
24. Nelson HS, Corticosteroid dosing and asthma control (Editorial) Ann Allergy Asthma and Immunol 2001; 86:599-602
25. Nelson HS, What is “more effective asthma control”? Reply J Allergy Clin Immunol 2001;107:1108-9
27. Nelson HS, Fluticasone propionate/salmeterol combination. Reply J Allergy Clin Immunol 2001;107:746
28. Flockhart DA, Nelson HS. Single isomer versus racemate: Is there a difference? Clinical comparisons in allergy and gastroenterology. CNS Spectrums 2002;7(4, suppl 1):23-27.
29. Ong PY, Cott G, Gutierrez M, Nelson HS. Unresponsive wheezing to asthma therapy in a 32-year-old female. Ann Allergy Asthma Immunol 2003;90:199-202
30. Anand MK, Nelson HS, Dreskin SC. A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria (letter to the editor). J Allergy Clin Immunol 2003;111:1133-5.
31. Asthma: A Guide for Patients. Harold S. Nelson. Health InfoNet Inc San Ramon. California 2004
32. Wenzel SE, Corren J, Kraft M, Meltzer EO, Nelson HS, Stoloff SW, Tashkin DP, Yawn BP Management of asthma in primary care settings. J Family Practice 2005; Sept: Supplement
33. Oppenheimer J, Nelson HS Skin testing in allergy diagnosis. Clin Lab Int 2006;30:8-11.
34. Nelson HS, Dorinsky PM. Safety of long-acting b-agonists. Letter to the Editor. Ann Intern Med 2006;145:706.
35. Cox L, Li JT, Nelson HS, Lockey R. Allergen immunotherapy: A practice parameter second update .J Allergy Clin Immunol 2007;120:S25-85.
36. Busse WW, Boushey HA, Camargo CA Jr., Evans D, Foggs MB, Janson SL, Kelly HW, Lemanske RF, Martinez FD, Meyer RJ, Nelson HS, Platts-Mills TAE, Schatz M, Shapiro G, Stoloff S, Szeffler SJ, Weiss ST, Yawn BP. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Summary Report 2007. J Allergy Clin Immunol 2007;120, No.5. Suppl: S94-S138.
37. Nelson HS. Preparing and mixing allergen vaccines for subcutaneous immunotherapy. Clin allergy Immunol 2008;21:303-20.

38. Nelson HS. The National Asthma Education and Prevention Program 2007 Revision of the Asthma Treatment Guidelines. Johns Hopkins University School of Medicine Advanced Studies in medicine 2008;8:64-9.
39. Nelson HS. Jack Pepys' contributions to the medical literature. J Allergy Clin Immunol 2009;123:720-3.
40. Casale TB, Cononica GW, Bousquet J, Cox L, Lockey R, Nelson HS, Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009;124:665-70.
41. Canonica W, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawanker R, et al Sublingual Immunotherapy: World Allergy Organization Position Paper 2009_WAOJ 2009;2:233-71. Allergy 2009;91:1-59.
42. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Emmett AH, Ortega H,A. Meeting the obligation to balance bioethics and clinical trial design in asthma (Editorial response) Am J Respir Crit Care Med 2010;181:648-50.
43. Cox L, Nelson HS, Lockey R. Allergen immunotherapy: A practice parameter Third Update .J Allergy Clin Immunol 2011;127:S1-S55.
44. Durham SR, Nelson HS. Allergen immunotherapy: a centenary celebration. World Allergy Organ J 2011;4:104-6.
45. Blaiss M, Nelson HS, Durham SR, Dahl R, Bufe A. Reply to correspondence on Nelson HS et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80. J Allergy Clin Immunol 2011;128:
46. Nelson HS. SCIT: Standard schedules, administration techniques, and monitoring. UpToDate Posted February 17, 2011.
47. Nelson HS. SCIT: Preparation of allergen extracts for therapeutic use. UpToDate Posted February 18, 2011.
48. Nelson HS. Maintenance of Certification: SUBCUTANEOUS Immunotherapy. J Allergy Clin Immunol 2011: 128:907-.
49. Bernstein DI, Blaiss MS, Cox LS, Finegold I, Lanier BQ, Nelson HS, Wallace DV. Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist. Ann Allergy Asthma Immunol 2011;107:422-5.
50. Blaiss M, Nelson HS, Durham SR, Dahl R, Bufe A. Reply to: Sublingual immunotherapy: Allergen specific or placebo effect? J Allergy Clin Immunol 2011;128:430
51. Nelson HS. Immunotherapy, for First Consult (a web based information service).
52. Nelson HS What will allergen immunotherapy look like in the future? Ann Allergy Asthma Immunol 2012;109:87-9.
53. DES Larenas-Linnemann, I Finegold, H Nelson. Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard. Ann Allergy Asthma Immunol 2012;109:609.
54. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma and Immunology/European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96
55. Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA2013;309:1278-88.

56. Calderon MA, Andersen JS, Nelson HS. Are meta-analysis-based comparisons solid evidence? *J Allergy Clin Immunol* 2013:
57. Calderon MA, Casale T, Cox L, Adkis CA, Burks AW, Nelson HS, Jutel M, Demoly P. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *Allergy* 2013;68:825-8.
58. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: A call for more rigorous clinical studies. *J Allergy Clin Immunol* 2013;132:1322-36.
59. Hoyte FC, Meltzer EO, Ostrom N, Nelson HS, Bensch G, Spangler DL, Storms WW, Weinstein SF, Katial RK. Recommendations for the Pharmacologic Management of Allergic Rhinitis. *Allergy, Asthma Proc* 2014;35:S20-S27.
60. Canonica, G. W., Cox, L., Pawankar, R., Baena-Cagnani, C. E., Blaiss, M., Bonini, S., Bousquet, J., Calderon, M., Compalati, E., Durham, S. R., van Wijk, R. G., Larenas-Linnemann, D., Nelson, H., Passalacqua, G., Pfaar, O., Rosario, N., Ryan, D., Rosenwasser, L., Schmid-Grendelmeier, P., Senna, G., Valovirta, E., Van Bever, H., Vichyanond, P., Wahn, U., and Yusuf, O. (2014) Sublingual immunotherapy: World Allergy Organization position paper 2013 update. *World Allergy Organ. J* 2014; 7, 6-57 .
61. Oppenheimer J, Durham S, Nelson H, Wolthers OD. Allergy Diagnostic Testing. WAO Website 2014.
62. Jutel M, Agache JM, Boini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Fee R, Sampson H, Du TG, Werfel T, van Wijk R, Zhang L, Akdis CA. International Consensus on Allergy Immunotherapy. *J Allergy Clin Immunol* 2015: 136:556-68.
63. Jutel M, Agache I, bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Santos AF, Du Toit G, Werfel T, Gerth van Wijk R, Zhang L, Akdis CA. International Consensus on Allergen Immunotherapy II. Mechanisms, standardization, and pharmacoconomics. *J Allergy Clin Immunol* 2016;137:358-68.
64. Nelson HS, Calderon MA, Bernstein DI, Casale TB, Durham SR, Andersen JS, et al. Allergen immunotherapy clinical trial outcomes and design: working toward harmonization of methods and principles. *Curr Allergy Asthma Reports* 2017;17:18
65. Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, et al. Sublingual Immunotherapy: A focused allergen immunotherapy practice parameter update. *Ann Allergy Asthma Immunol* 2017;118:276-282.
66. Wise SK, Lin SY, Toskala E, Orlandi R, et al (Nelson HS). International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. *Internat Forum allergy Rhinol* 2018;8:108-352.
67. Wheatley LM, Wood R, Nadeau K, Liu A, Zoratti E, Bacharier L, Brittain E, Calderon M, Casale T, Chipps B, Cox L, Creticos PS, Desai M, Dreborg S, Durham S, gergen PJ, Gruchalla R, Nelson H, O'Hehir RE, Plaut M, Schwaninger JM, Tilles S, Vickery B, Wittenberg KM, Togias A. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy – An NIAID/AHRQ Workshop. *J Allergy Clin Immunol* 2019;143:1711-1726.
68. Nelson HS. 2020 updates asthma guidelines: allergen immunotherapy. *J Allergy Clin Immunol* 2020;146:1286-1287.
69. Calderon MA, Wasserman S, Bernstein DI, Demoly P, Douglass J, Gagnon r, Katelaris CH, Kim H, Nelson HS, Okamoto Y, Okubo K, Virchow JC, DuBuske L, Casale TB, Canonica GW, Nolte H. An international panel of experts using scientific data to the clinical practice of allergen immunotherapy for allergic

rhinoconjunctivitis and asthma: A Rostrum paper. JACI Pract 2020 May 15; S2213-2198 (20)30479-7.

70. Prescribing, Adjusting and stopping AIT. AAAAI Slide course. 2022.
71. Calderon MA, Casale TB, Nelson HS, Bacharier LB, Bansal P, Bernstein DI, et al. Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States. J Allergy Clin Immunol Pract 2023;11:1100-1115.
72. Nelson HS. The 2022 Allergy Literature Review – Editorial. Ann Allergy Asthma Immunol 2023;130:137-8.
73. Oppenheimer JJ, Nelson HS. 80 years of skin testing evaluation in Annals. Annals of Allergy, Asthma & Immunology 2023;131:287

SELECTED INVITED PRESENTATIONS:

Association of Convalescent Pediatric Hospitals Annual Meeting, Phoenix, Arizona, February, 1978. "Beta adrenergic blockade, cause of asthma or result of therapy."

Second International Food Allergy Symposium, Mexico City, October, 1978. "Allergic reactions to ingested drugs."

Second International Food Allergy Symposium, Mexico City, October, 1978. "Reactions to dyes and preservatives in patients with bronchial asthma."

National Asthma Center, Asthma Conference. Keystone, Colorado, January, 1979. "Adverse reactions to drugs."

Pennsylvania Allergy Society, Hershey, Pennsylvania, June, 1979. "Beta adrenergic subsensitivity and clinical usefulness."

Pennsylvania Allergy Society, Hershey, Pennsylvania, June, 1979. "Extract variables in immunotherapy."

Eighth Annual Symposium NJH/NAC, Keystone, Colorado, January, 1980. "Allergy immunotherapy."

Annual Post Graduate Program, Association for the Care of Asthma, Miami Beach, Florida, January, 1980. "Allergen selection and handling."

American Thoracic Society Annual Meeting, Washington, DC, May, 1980. "Clinical aspects of aspirin sensitivity."

37th Annual Congress American College of Allergists, Washington, DC, April, 1981. "Evaluation of sensitivity, reproducibility, reliability of different methods in skin testing."

Allergy Update 1981. Walt Disney World, Florida, January, 1981. "Immunotherapy in allergic disease."

Oklahoma State Medical Society Annual Meeting, Afton, Oklahoma, May, 1981. "Readministration of drugs to patients with a history of a previous adverse reaction."

American College of Chest Physicians Annual Meeting, San Francisco, California, October, 1981. "Immunologic approaches to the diagnosis of drug allergies."

American College of Allergists Annual Meeting, Miami Beach, Florida, January, 1982. "The clinical relevance of IgE."

NJH/NAC Keystone Conference, Keystone, Colorado, January, 1982. "Allergy immunotherapy."

Michigan Allergy Society, Dearborn, Michigan, February, 1982. "Beta adrenergic agonists: Clinical efficacy and development of subsensitivity."

Asthma Update 1982, Long Beach, California, 1982. "Do allergy shots work?"

Asthma Update 1982, Long Beach, California, 1982. "Occupational asthma."

Kentucky Medical Association Annual Meeting, Lexington, Kentucky, September, 1982. "Anaphylaxis: Diagnosis and treatment."

Allergy-Immunology Section, Kentucky Medical Association, Lexington, Kentucky, September, 1982. (1) "Atopy: Review of classic studies," (2) "Occupational asthma," (3) "Immunotherapy in allergic asthma."

American Academy of Allergy "Hot Line", April, 1982. "Adverse reactions to local anesthetics."

Current Views in Allergy and Immunology, Volume 9, September, 1982. "Beta adrenergic agonists: Clinical usefulness and development of tolerance."

Greater Washington Allergy Society, December, 1982. "Immunotherapy."

Sixth Annual Buffalo Symposium on Pediatric and Adult Allergy, Toronto, Canada, July, 1983. (1) "Immunotherapy of rhinitis/asthma: Old and new preparations," (2) "Gastroesophageal reflux in lung disease."

Cromolyn in Allergy Symposium, Snowmass Village, Colorado, June, 1983. "The use of cromolyn in ocular disease: Vernal keratoconjunctivitis."

Second International Workshop on Sustained-Release Theophylline. Mont Ste Marie, Canada, September, 1983. "Combination of oral theophylline and aerosolized beta₂ agonists."

American College of Allergists Annual Meeting, San Francisco, California, April, 1984. (1) "Stepwise therapy of bronchial asthma: Beta agonists," (2) "Readministration of local anesthetics to patients with a history of a previous reaction."

NJH/NAC Keystone Summit on Allergy, Immunology, Pulmonary and ENT, Keystone, Colorado, February, 1984. "Immunotherapy of rhinitis/asthma: Old and new preparations."

Corsendonck, Turnhout, Belgium, March, 1984. "The effect of long-term administration of beta adrenergic stimulants on the clinical efficacy of these drugs."

Greater Washington Allergy Society, September, 1984. "Beta adrenergic agonists: Clinical usefulness and development of tolerance."

The Allergy-Immunology Section of the American Osteopathic Medical Association, Las Vegas, Nevada, November, 1984. "Diagnostic tests in Allergy."

Kaiser Permanente Allergy Symposium Workshop, Koto De Caza, California, December, 1984. "New approaches in the treatment of severe anaphylaxis."

Kaiser Permanente Allergy Symposium Workshop, Koto De Caza, California, December, 1984. "Aspects of immunotherapy."

Kaiser Permanente Allergy Symposium Workshop, Koto De Caza, California, December, 1984. "Update on drug induced beta hyporesponsiveness: Its clinical significance."

NJH/NAC Keystone Summit on Allergy, Immunology, Pulmonary and ENT, Keystone, Colorado, January, 1985. "Beta adrenergic therapy of bronchial asthma."

Annual Congress of the American College of Allergists, Bal Harbour, Florida, February, 1985. "Atopic Diseases. Bela Schick Lecture."

NJH/NAC Keystone Summit on Allergy, Immunology, Pulmonology, and Pharmacology, Keystone, Colorado, January, 1986. "Immunotherapy of rhinitis and asthma."

Current Views in Allergy and Immunology, January, 1986. "Diagnostic tests in allergy."

The Wylder Lectures, New Mexico Pediatric Society, Albuquerque, New Mexico, March 1, 1986. 1) "Atopic Diseases: Definitions for the Pediatrician" and 2) "Diagnostic and Laboratory Tests in Allergy."

The 118th Annual Session of the Nebraska Medical Association, Omaha, Nebraska, April 26, 1986. "Diagnostic Testing in Allergy and Beta Adrenergic Agents -- Clinical Use and Sub-Sensitivity."

Symposium on New Approaches in the Evaluation of Anti-Asthmatic Drugs. Joint Meeting Societas Europaea Pneumologica and Societas Europaea Physiologiae Clinicae Respiratoriae. Paris, France, September 3, 1986. "Clinical evaluation of anti-asthmatic drugs in long term administration."

29th Annual Meeting, Society of Air Force Physicians, New Orleans, Louisiana, March 25, 1987, Philip G. Keil Memorial Lecture. "Beta-adrenergic bronchodilators in the treatment of asthma."

Half-day Tachyphylaxis Workshop. April 2, 1987. The Royal Society of Medicine, Wimpole Street, London, England. "Skin Test Suppression by Antihistamines and the Development of Subsensitivity."

Annual Meeting, Texas Allergy Society, Houston, Texas. May 16, 1987. 1) "Beta-adrenergic therapy of bronchial asthma." 2) "The atopic diseases."

San Diego Allergy Society, September 16, 1987. "Assessment and management of bronchial asthma."

Florida Allergy Society, September 19, 1987. 1) "Environmental control - what is known to be useful." 2) "Treatment of status asthmaticus."

Western Society of Allergy and Immunology, Lake Tahoe, California. October 15-17, 1987. 1) "Environmental control measures in allergy." 2) "Beta Agonists: Update on their current usage. October 15-17, 1987."

American College of Physicians Annual Meeting, New York, New York. October 1987. "Bronchodilator therapy of asthma."

American College of Allergists Annual Meeting, Boston, Massachusetts. November 16, 1987, workshop "Bronchodilator therapy of status asthmaticus"

Allergy and Immunology Society of Georgia. Atlanta, Georgia. November 20, 1987. "Skin testing: Pitfalls in the diagnosis of allergic diseases" and "Inhalation therapy in the treatment of asthma."

Respiratory Disease and the Total Airway: An Evolving Concept. January 3-5, 1988. Acapulco, Mexico. "Bronchodilator Therapy."

Environmental Aeroallergens and Pollution: Effectiveness of Air Cleaning Devices. St. Petersburg, Florida, January 16, 17, 1988. "Report from the Ad Hoc Committee on Residential Room Air Cleaning Devices."

69th Annual Session, American College of Physicians, New York, New York, March 3-6, 1988. "Update in Allergy and Immunology."

7th Medical Command, 39th Annual Medical Surgical Clinical Congress, Garmisch, Germany, May 16-19, 1988. "Asthma: Evaluation and Treatment."

Bronchial Challenges Symposium, Fort Lauderdale, Florida, May 19-22, 1988. "Clinical Usefulness of Immediate Skin Tests."

Louisiana State Allergy Society, New Orleans, Louisiana, June 25-26, 1988. "Beta Adrenergic Bronchodilators: Clinical Usefulness and Development of Tolerance" and "Diagnostic Tests in Allergy."

American College of Allergy and Immunology Annual Meeting, Los Angeles, November 13, 1988. Plenary Session "Differential Diagnosis of the Wheezing Adult."

Colorado Regional Meeting, American College of Physicians. Colorado Springs, Colorado, January 21, 1989. "Treatment of Asthma as an Inflammatory Disease."

Southwest Allergy Forum. Scottsdale, Arizona, April 6-9, 1989. "Management of Bronchial Asthma with Emphasis on Sympathomimetic Drugs." "Diagnosis in Allergic Disease." "Corticosteroids - Systemic and Topical - Old and New." "Immunotherapy in Allergy."

47th Annual Course in Allergy and Clinical Immunology, University of Minnesota. Minneapolis, Minnesota, April 14, 1989. "Clinical Approach to Bronchial Asthma." "Pharmacologic Agents Directed Against the Immediate Airway Reactions."

Annual Meeting Colorado Society for Respiratory Care, Breckenridge, Colorado, June 8, 1989. "Hand Held Nebulizers vs. Metered Dose Inhalers."

Los Angeles Society of Allergy and Clinical Immunology, October 7, 1989, Los Angeles, California. "Immunotherapy - where are we in 1989?", and "Environmental Control and Air Cleaners in Allergic Diseases"

Allergy Association of North California. October 30, 1989, San Francisco, California. "Immunotherapy."

American College of Allergy and Immunology Annual Meeting, November 14, 1989, Orlando, Florida. The Jaros Lecture: "Natural History of Asthma."

Internal Medicine, Grand Rounds - Buffalo General Hospital, Buffalo General Hospital, Buffalo, New York, March 7, 1990, "Allergy Immunotherapy for rhinitis and asthma: Recent Developments."

American Academy of Allergy and Immunology - Annual Meeting, Baltimore, Maryland, March 24-28, 1990 Workshop presentations: 1) "Allergic and pseudo-allergic reactions to excipients in drug preparations." 2) "Allergic reactions to drugs employed in the treatment of asthma and allergies."

Greater Phoenix Allergy Society, April 29, 1990 "Treatment of Asthma in the 1990's."

Texas Medical Association Annual Meeting,, Section on Allergy, Asthma and Clinical Immunology. Corpus Christi, Texas April 12, 1990. 1) "Current Status of Immunotherapy" 2) "Skin Testing."

Northern California Allergy Foundation San Francisco, California September, 1990. 1) "Aerosol therapy for bronchial asthma" 2) "Allergy Immunotherapy: Where are we in 1990?"

Western Society of Allergy and Immunology 29th Annual Scientific Session. Colorado Springs, Colorado. October 11-13, 1990. 1) "Alternatives for the Treatment of the Refractory Asthmatic" 2) "The Natural History of Asthma."

American College of Allergy and Immunology Annual Meeting, San Francisco, California November 10-14, 1990. 1) Plenary Session: "In Vivo Assays for the Diagnosis of Allergy: A Comparison of Techniques." 2) "Beta Agonists Revisited: The McGovern Lecture."

North Central Allergy Society Annual Meeting, Minneapolis, MN 6 April 1991. "Update on Immunotherapy."

American College of Physicians Annual Meeting, New Orleans, Louisiana. 14 April 1991 "Bronchodilator Therapy of Asthma."

Southwest Allergy Forum – San Antonio, Texas – 19 April, 1991. "Standardized extracts in Allergy Practice."

Georgia Allergy Society. Stouffer Pineisle Resort – Lake Lanier, Georgia — 27 April 1991. 1) "The use of skin testing in allergic disease;" 2) "Immunotherapy update."

Asthma Update: Mechanisms & Therapy. Annual Meeting, Texas Medical Association. Dallas, Texas - May 11, 1991. "Inflammatory Basis of Asthma."

Virginia Allergy Society - Virginia Beach, VA 15-16 June, 1991: 1) Current status of Immunotherapy; 2) Future trends in immunotherapy.

American College of Physicians. Current Concepts in Internal Medicine. San Francisco, CA. 25 October, 1991. "Current Trends in Therapy of Bronchial Asthma."

American College of Chest Physicians Annual Meeting. San Francisco, CA. 4 November 1991. Postgraduate Symposium on Bronchial Asthma - "Bronchodilators."

American Academy of Allergy and Immunology Annual Meeting. New York, New York 16-20 November, 1991. 1) Plenary Session "Can a Priority of Drug Therapy be Established?" 2) "Point counter point - Is regular use of beta-agonists appropriate in bronchial asthma?"

Illinois State Society of Allergy and Clinical Immunology 25 November, 1991. "Immunotherapy - Current Aspects." Chicago, IL.

American Academy of Allergy and Immunology, Orlando, Florida. 6-11 March 1992. "Current controversies in asthma therapy - should beta-agonists be used on a regular basis."

American Thoracic Society Annual Meeting, Miami Beach FL, 19 May, 1992. Clinical controversies I. "Is Beta-Agonist Therapy associated with increased risk in the treatment of asthma.? CON."

The 15th National Conference on Pediatric/Adult Allergy and Clinical Immunology. Toronto, Ontario, Canada. 17-19 July 1992. 1) The beta agonist bronchodilator controversy. 2) Skin tests: techniques and interpretation.

The First National Conference on Asthma Management. Crystal City, Virginia. 11-13 October 1992. "Clinical Asthma Update: Immunotherapy."

42nd Annual Meeting of the Japanese Society of Allergology. Sendai, Japan. 28-30 October 1992. 1) "The role of the environment in the increasing prevalence of bronchial asthma." 2) "Peak expiratory flow monitoring in the management of bronchial asthma in the United States."

American College of Allergy and Immunology Annual Meeting, November 13-17, 1992, Chicago, Illinois. 1) Plenary Session: "Potential adverse effects of beta-agonist," 2) Workshop - "Clinical and research uses of skin testing," 3) Workshop - "Immunotherapy - beyond the basics."

The Allergy Foundation of Northern California Educational Symposium "What's Hot in Allergy" January 16-17, 1993. Squaw Valley, California. 1) "Controversies in Beta Adrenergic Agonist Therapy of Asthma," 2) "Use of Peak Flow Monitoring in the Management of Bronchial Asthma."

American Academy of Allergy and Immunology Annual Meeting, Chicago, IL. 13-17 March 1993. 1) "Association of Military Allergists: History of Allergy Research in the Military," 2) Workshop - "Skin Test Proficiency."

Sixth Eastern Allergy Conference, Bermuda 15-17 April 1993. "Issues Related to Allergen Mixes."

American Society of Hospital Pharmacists Annual Meeting, Denver, Colorado 5-10 June 1993. Symposium Improving the Outcome of Asthma: A National Strategy 1) "The National Asthma Education Program," 2) "Inhaled Beta Agonist Therapy: Current Controversies."

VIII International Food Allergy Symposium. Denver, Colorado. 9-11 July 1993. "Prospects for food allergy immunotherapy."

California Society of Allergy and Clinical Immunology. Annual Meeting, Ojai, California. 30 July 1993. "Topical Inhaled Steroids - How topical are they?"

Rhinitis and Sinusitis: Controversies and treatment. 22 October 1993, Washington. "Treatment of rhinitis"

Kaiser Permanente of Northern California Annual Allergy Symposium. 30 October 1993. 1) "Immunotherapy: Therapeutic Considerations" 2) "The Role of Beta Agonists in the Treatment of Asthma."

American College of Allergy and Immunology Annual Meeting, 13-17 November 1993. Atlanta, Georgia. 1) Sixth Annual Recent Literature Review: "Immunotherapy." 2) Workshop - "Skin Testing the Basics." 3) Plenary Session: "Immunotherapy: The How's and Why's."

The Third Annual IBC Conference: New Approaches for the Treatment of Allergic Diseases & Asthma. December 2-3, 1993. Washington, DC. "The Beta Adrenergic Controversy - Their Role in Asthma Management."

Thailand Allergy and Immunology Society. Bangkok, Thailand. 10 January 1994. 1) "Allergy Immunotherapy: Clinical Aspects." 2) "Beta-Adrenergic Controversy."

Greater Kansas City Allergy Society. Kansas City, Missouri. 22 January 1994. 1) "Beta-Adrenergic Controversy." 2) "Variables in Immediate Skin Testing."

Western Society of Allergy and Immunology. Mauna Lani, Hawaii. 23-27 January 1994. 1) "Clinical Studies of Long Acting B2-Agonists," 2) "What Allergens Should We Test For/Treat To?"

Fitzsimons 23rd Annual Allergy/Immunology Symposium. 31 January 1994. Aurora, Colorado. "Corticosteroids."

Annual Meeting American Academy of Allergy and Immunology. Third Annual Fellows in Training Symposium. Anaheim, California, 4 March 1994. "Evaluation of Skin Test Devices."

Seventh Eastern Allergy Conference/Southwest Allergy Forum. Palm Beach, Florida. 7-10 April 1994. "Variables in Allergy Skin Testing."

Visiting Charles Reed Lecturer to the Allergy Immunology Division, Mayo Clinic. Rochester, Minnesota. 14 April 1994. "Variables in Allergy Skin Testing."

Utah Allergy Society, Salt Lake City, Utah, 22 April 1994. "Beta Adrenergic Controversy."

One Hundred Ninety Sixth Annual Meeting of the Medical and Chirurgical Faculty of Maryland, Maryland Asthma and Allergy Society. Haggartown, Maryland. 14 May 1994. "Beta-Agonists: Current Issues and Controversies."

Wyoming Medical Society Annual Meeting, Jackson Hole, Wyoming. 10 June 1994. "New Trends in Asthma Therapy."

Curso de Actualizacion Medica Asma Bronquial. Centro Medico Docente La Trinidad. Caracas Venezuela. 18 June 1994. 1) "Increasing Prevalence of Bronchial Asthma: Evidence of the Relation With Changes in Indoor Allergen Exposure" 2) "Controversies Regarding the Use of Beta Adrenergic Bronchodilators and Studies with the Long Acting Beta Agonist."

Thirteenth Annual Professional Symposium of the American Lung Association of Ventura County and the American Thoracic Society. 23 September 1994. "The Role of the Indoor Environment in the Increasing Prevalence of Asthma."

Connecticut Allergy and Immunology Society. 29 September 1994. "Variables in Allergy Skin Testing".

American College of Allergy and Immunology Annual Meeting, San Francisco, California. 4-9 November 1994. "Seventh Annual Literature Review-Immunotherapy." "New Drug Therapy for the Treatment of Asthma." "New Developments in Five Lipoxygenase Inhibitor Therapy - Results of Clinical Trials."

First Interhospital Meeting and Twelfth Meeting of the Executive Committee of the Buenos Aires Municipal Program for the Prevention and Control of Bronchial Asthma. Buenos Aires, Argentina. 11 November 1994. "New Guidelines in the Treatment of Asthma."

The 1995 International Conference. American Academy of Allergy and Immunology. New York, New York. 24 February - 4 March 1995. FIT/AAAAI Symposium - Practicing Allergy in the Office Setting, "Rush Immunotherapy." Symposium Advances in Therapy for Allergic Rhinitis, "Treatment Modalities and Current Therapy."

V Brazilian Congress of Pediatric Allergy and Immunology; II Pan-American Congress of Pediatric Allergy and Immunology. Sal Paulo, Brazil. 18-22 March 1995. Satellite Symposium - Advances in Asthma Treatment. "Oral Corticotherapy in Asthma."

Second Annual Fellow's Symposium. Seattle, Washington. 20 May 1995. "Asthma Evaluation and Development of an Appropriate Treatment Plan."

The Forty-Seventh Annual Meeting - Pennsylvania Allergy Association. Hershey, Pennsylvania. 22-25 June 1995. 1) "Asthma Pharmacotherapy - A Balanced Approach" 2) "Variables in Allergy Skin Testing."

The Forty-Fifth Annual Scientific Assembly - The Virginia Academy of Family Physicians. Williamsburg, Virginia. 20-23 July, 1995. A. Epes Harris MD Memorial Lecture. "Asthma 1995 - A Changing Concept."

New Challenges in Managing Asthma. Princeton, New Jersey. 10 August 1995. "What is the Role of Bronchodilators in Asthma?"

IV Congreso Nacional De Alergia E Inmunologia Pediatrica Y Jornadas Anuales De Pediatria. Chihuahua, Mexico. 22-25 August 1995. 1) "Clinical Relevance of Skin Tests in Allergic Diseases" 2) "Adequate Administration of Specific Immunotherapy in Allergic Patients."

The 1st Astra Draco Annual Research Seminar. Lund, Sweden. 7-8 September 1995. "Childhood Asthma Management Program (CAMP)."

The Second Norman A. Sterrie Lecture. Park Nicollet Clinic, St. Louis Park, Minnesota. 12 October 1995. "Variable in Allergy Skin Testing." Presentation, part of Allergy and Pulmonary Update. 13 October 1995, "Asthma Management /Strategy for the '90's."

The Los Angeles Allergy and Immunology Society. Los Angeles, California. 16 September 1995. "Future Modalities of Allergy Immunotherapy."

Trans-Pacific Allergy and Immunology Society. Fort Douglas, Australia. 27 October 1995. "Variables of Skin Testing."

Joint Meeting Trans-Pacific Allergy and Immunology Society and Australian Society of Clinical Immunology and Allergy. Sidney, Australia. 30 October 1995. "Controversy in Asthma Management: (1) Beta Agonist, (2) Immunotherapy."

American College of Allergy, Asthma & Immunology Annual Meeting. Dallas, Texas. 10-15 November 1995. "Plenary Presentation: A Rational Approach to Immunotherapy."

University of Texas at Houston Medical Grand Rounds. 5 December 1995. Subject: "Controversies regarding the use of β -agonist in the treatment of asthma."

New Jersey Allergy Society Winter Meeting, Summit, New Jersey. 10 January 1996. "The Increasing Prevalence of Asthma, its Relation to the Indoor Environment."

Hawaii. 22-23 January 1996. 1) Kuakini Medical Center. 22 January 1996. "Asthma Update: Diagnosis and Management." 2) Hawaii Allergy Society. 22 January 1996. "The Increasing Prevalence of Asthma, Potential Causes." 3) Medical Grand Rounds, Triplor Army Medical Center. 23 January 1996. "New Drugs in the Treatment of Asthma." 4) Hawaii Medical Service Association. 23 January 1996. "Asthma Update: Current Trends and Issues."

The Eighteenth Annual Update on Allergy and Clinical Immunology, Keystone, Colorado. 10 February 1996. "Is There a Role for Long-Acting Beta-Agonist?"

The Thirty-Fifth Annual Durrence-Waring Midwinter Chest Conference, Aspen, Colorado. 23 February 1996. "Is Allergen Immunotherapy Effective in Asthma?"

American Academy of Allergy, Asthma and Immunology Annual Meeting, New Orleans, Louisiana 16-20 March 1996. 1) 17 March 1996. "Status of Immunotherapy with Foods." 2) 19 March 1996. "Immunotherapy: An Overview."

Missouri State Allergy Association Annual Meeting. 13 April 1996. "Leukotriene Antagonist - New Treatment Options for Asthma."

Allergy Immunology Rounds, Department of Pediatrics, McMaster University, Hamilton, Ontario. 19 April 1996. "Allergy Immunotherapy Present and Future."

Allergy Update 1996, Toronto, Canada. 20 April 1996. "Immunotherapy, an Overview."

Illinois Society of Allergy and Immunology. 22 April 1996. "The Beta-Adrenergic Controversy."

Fourteenth Annual Aspen Allergy Conference, Aspen, Colorado. 24 July 1996. "Topical Immunotherapy - State of the Art Lecture."

Seventeenth Annual Post Graduate Course Alabama Society of Allergy and Immunology, Destin, Florida. 9-11 August 1996. "Alternatives in Immunotherapy." "Increasing Prevalence of Asthma - the Relation to the Indoor Environment." "Controversies in Asthma Therapy: Inhaled Beta-Agonists."

San Diego Allergy Society, La Jolla, California. 25 September 1996. "New Directions in Immunotherapy."

Illinois Society of Allergy and Immunology. 22 October 1996. "Alternative Approaches to Immunotherapy."

Albuquerque Asthma Day - An Update on Asthma Management, Albuquerque, New Mexico. 23 & 24 November 1996. "Stepwise therapy in asthma management: inhaled steroids, β -agonists, cromolyn/nedocromil, theophylline."

Family Practice Chief Resident Symposium, Palm Beach, Florida. 12-15 December 1996. "Allergic Rhinoconjunctivitis."

Annual Meeting American College of Allergy, Asthma & Immunology, Boston, Massachusetts. 8-13 November 1996. "Plenary Presentation: Topical Immunotherapy" "Recertification Symposium: Pharmacotherapy."

Combined Allergy Immunology Meeting, Acapulco, Mexico. 16-18 January 1997. "Immunology and Asthma" "In Vivo Testing for IgE Mediated Disease."

Western Society of Allergy & Immunology 35th Annual Scientific Session. 19-23 January 1997. "Comparison of Anti-Inflammatory Treatments for Asthma" "Future Modalities of Immunotherapy."

American Academy of Allergy, Asthma, and Immunology Annual Meeting. San Francisco, California. 21-26 February 1997. 1) Fellows in training symposium, "Clinical Use of Standardized Extracts," 2) Symposium on Asthma 1997 knowledge base on control and treatment, "What is the role of leukotriene antagonist."

Medical Grand Rounds, Rose Medical Center. Denver, Colorado. March 1997. "Asthma Therapy."

Literature Review Course. Chicago, Illinois. 9 March 1997 "Allergen Immunotherapy."

Indiana Allergy and Immunology Society. 9 April 1997 "New Developments in Asthma Therapy."

Tufts Allergy Seminar 16 April 1997 "Future Trends in Allergen Immunotherapy."

The Third International Consensus Conference on Allergology and Clinical Immunology. Rome, Italy. 20-23 April 1997 "Immunotherapy with Foods."

Medical Grand Rounds at Statten Island University Hospital. Statten Island, New York. 7 May 1997 “The Increasing Prevalence of Asthma: Possible Causes.”

The Greater New York Allergy and Immunology Society. 7 May 1997 “Clinical Use of Standardized Extracts.”

The Kentucky Allergy Society. Louisville, Kentucky. 17 May 1997 “Variables in Allergy Skin Testing” and “Leukotriene Inhibitors in Asthma.”

Evening Symposium: Levalbuterol: Advancing Asthma Therapy Through Purer Medicine. San Francisco, California 19 May 1997 “Clinical Phase III Studies With Levalbuterol.”

American Thoracic Society 1997 International Conference. San Francisco, California. National Asthma Education and Prevention Program: Expert Panel Guidelines Update Report. 20 May 1997 “Factors Contributing to Asthma Severity.”

VI Curso Internacional de Inmunologia y Padecimientos Alergicos “Dr. Julio Cueva”, Hospital Juárez De Mexico, Mexico City, Mexico. 7-11 July 1997. *Inmunoterapia Topica Metodologia e Indicaciones*.

60th Annual Sheldon Society Meeting, The University of Michigan Medical School, Ann Arbor, Michigan. 11-13 July 1997. “The New Asthma Treatment Guidelines.”

University of Colorado Health Sciences Center, Department of Medicine Grand Rounds, Denver, Colorado, 3 September 1997. “Outpatient Management of Asthma: Outcomes and Cost Implications.”

San Antonio Allergy and Asthma Society, San Antonio Texas, 11 September 1997. “New Guidelines for the Diagnosis and Management of Asthma.”

Wilford Hall United States Air Force Medical Center, Medical Grand Rounds, 12 September 1997. “Outpatient Management of Asthma.”

I Congresso Brasileiro de Asma, Sociedade Brasileira de Pneumologia e Fisiologia. Natal, Brazil 15-19 September 1997. *Conferência Internacional*: 1) *Asma resistente a esteróides*. 2) *Beta agonistas avanços e recuos*. 3) *Imunoterapia: estado atual*.

The New England Allergy Society, Annual Symposium, Mystic Connecticut, 25-26 October 1997. “Immunotherapy for Anaphylactic Sensitivity to Foods,” and “Gastroesophageal Reflux and Asthma.”

American College of Allergy, Asthma and Immunology Annual Meeting, San Diego, California, 7-12 November 1997. 1) “Literature Review: Immunotherapy.” 2) “Pharmacotherapy of Severe Asthma.” 3) “Are All Steroids Created Equal.”

Family Practice Chief Residents Training Program in Allergy, Asthma and Immunology, Phoenix, Arizona, 22 November 1997. “Immunotherapy.” Palm Beach, Florida, 13 December 1997. “Immunotherapy.”

The Trans-Pacific Allergy and Immunology Society, Maui, Hawaii, 13-17 January, 1998. “New NHLBI Guidelines for the Diagnosis and Management of Asthma,” and “Immunotherapy with Foods.”

Thirty-sixth Annual Scientific Session Western Society of Allergy and Immunology, Maui, Hawaii, 18-22 January, 1998. “Efficacy of Immunotherapy in Asthma.”

New Approaches for Diagnosis & Management of Asthma, Kirkland, Washington, 21 February, 1998. “Difficult Asthma Patients and New Treatment Modalities.”

Sutter Update on Asthma, Sacramento, California, 28 February, 1998. “New NHLBI Guidelines.”

American Academy of Allergy Asthma and Immunology Annual Meeting, Washington, D.C., 14-18 March, 1998. Workshop: “Practical Immunotherapy.” Symposium on Immunotherapy: “Local Nasal and Bronchial Immunotherapy.”

Pulmonary Grand Rounds, Temple University Hospital, Philadelphia, PA, 30 March, 1998. "Management of the Patient with Severe Asthma."

Dallas-Ft. Worth Allergy Society, Irving, Texas. 21 April, 1998. "Immunotherapy for Asthma: Does it Work?"

Internal Medicine Grand Rounds, St. Paul Medical Center, Dallas, Texas, 22 April, 1998. "The New NHLBI Guidelines."

Allergy Rounds, University of Texas School of Medicine, Dallas, Texas, 22 April, 1998, "Immunotherapy for Food Allergy."

Medical Grand Rounds, Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, 20 May, 1998, "Management of Severe Asthma,"

Allergy/Immunology Grand Rounds, Hahnemann University School of Medicine, Philadelphia, Pennsylvania, 20 May, 1998, "What is Optimal Management for Mild-Moderate Persistent Asthma?"

Frontiers in Research and Clinical Management of Asthma and Allergy, Johns Hopkins University School of Medicine, 29-31 May 1998. "The Emperor Has Many New Clothes: The New Inhaled Corticosteroid." "Alternate Routes of Delivery: Local Nasal IT." "Controversies in Allergy Immunotherapy in Asthma."

Creating Partnerships in Asthma Care, American Lung Association of Kansas, Topeka, Kansas. 12 June, 1998. "Inhaled Corticosteroids: Choices, Choices, Choices." "Adult Asthma: Medical Options."

Educational Conference, Creating Partnerships, American Lung Association of Kansas

Allergy and Immunology Society of Greater Portland, Portland Oregon "Update on Allergen Immunotherapy" September 8, 1998

St. Louis Allergy/Immunology Society, St. Louis, MO "The Role of Allergen Immunotherapy in Bronchial Asthma" September 10, 1998

Grand Rounds, University of St. Louis, School of Medicine, St. Louis, MO. "Guidelines to the Diagnosis and Management of Asthma" September 11, 1998.

Greater Houston Allergy/Immunology Society, Houston, TX, "Symposium on Allergen Immunotherapy. (1) Allergen Extracts Standardization, Mixing and Preservation of Potency. (2) Future Directions in Allergen Immunotherapy. October 10 1998

American College of Allergy, Asthma and Immunology Annual Meeting, Philadelphia, PA, November 6-10. 1998. Literature Review "Immunotherapy". Symposium: "Consequences of Untreated Asthma: An Evidence Based Approach". "What is the Natural History of Asthma? Can It's Effects be Altered?" Symposium Key Questions in The Management of Asthma, "What are the Key Clinical Concerns in Treating Asthmatic Adults"

Fellow Conference Schedule, The Mount Sinai Medical Center, New York, NY, "Alternative Approaches in Immunotherapy". January 22, 1999.

Allergy and Asthma Update '99, Allergy Foundation of Northern California, San Francisco, CA February 13, 1999.

National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Scientific Agenda, February 11, 1999, Washington, DC.

Medical Grand Rounds, Department of Medicine, University of California, San Diego, CA "Development of Guidelines for the Diagnosis and Treatment of Asthma" February 17, 1999.

American Academy of Allergy, Asthma and Immunology. Orlando Florida, "Is Asthma Severity Worsening"? February 27-March 3, 1999.

The 38th Annual Swineford Allergy Conference, University of Virginia School of Medicine, Charlottesville, VA, “Enzymes, Allergen Extracts and Immunotherapy”, April 9-10, 1999.

Texas Allergy and Immunology Society, Wyndham Anatole Hotel, Dallas, TX “Alternative Methods of Immunotherapy” and “Does Immunotherapy have a Role in the Treatment of Asthma?” May 7, 1999.

1999 American In-vitro Allergy Immunology Society Scientific program. Clinical Allergy Applications: Present and Future. “In-vivo Diagnostic Tests Used in Allergy”, May 21, 1999.

Childhood Asthma in the Next Millennium, “Asthma Treatment New and Old – Questions and Answers” June 11-12, 1999.

The Fifth Lloyd V. Crawford Symposium on Allergy and Clinical Immunology & the Tennessee Society of Allergy, Asthma and Immunology Meeting, Adams Mark Hotel, Memphis, TN. “The Use of Standardized Extracts in Allergy Practice” and “The Relationship Between Upper and Lower Airways” July 9-11, 1999.

Alabama Society of Allergy, Asthma and Immunology, 20th Annual Postgraduate Course, Sandestin Beach Hilton, Destin, Florida. “Epidemiology of Asthma” and “Update on Allergen Immunotherapy”, August 14-15, 1999

American College of Allergy, Asthma, and Immunology Annual Meeting, Chicago, IL, November 11-17, 1999 “Immunotherapy for Food Allergy” Literature review course: “Immunotherapy”; Workshop: “Allergen treatment: optimal dose”, November 14, “Three Meta-analyses of Allergen Immunotherapy: Asthma, Allergic Rhinitis and Venom Immunotherapy”, November 16, “Treatment Alternatives for Anti-inflammatory Therapy of Asthma”; 1) “Overview of Asthma Guidelines” and 2) “How much is enough – High Dose Steroids vs Steroid Sparing Agents.”

California ALA, Monterey, CA Advances in Diagnosis and Treatment, November 19, 1999, 1) “The Role of Allergies in Asthma”, 2) “New Developments in Beta-Agonist Therapy.”

Greater Kansas City Allergy Society, Immunotherapy Symposium, January 22, 2000. “Allergen Treatment: Optimal Dose.”

Northern California Allergy Society, San Francisco, CA, February 19, 2000. “Asthma Guidelines and Outcomes – How Effective are the Guidelines in Influencing the Outcomes of Asthma Therapy” Year 2000 Allergy and Asthma Update.

American Academy of Allergy, Asthma & Immunology Annual Meeting, San Diego, CA. March 5, 2000. “A New Paradigm: Is there more to Asthma than Inflammation?” “Clinical Evidence for Combination Therapy.”

The North West Allergy Forum, May 20, 1999, Victoria, British Columbia, Canada, Optimal Dose Immunotherapy and Use of standardized extracts.

Allergy for the Allergist, Texas Allergy and Immunology Society, May 26, 2000, San Antonio, Texas.

1) Use of Standardized Antigens, How much is enough? 2) High dose inhaled steroids versus steroids sparing agents.

Annual Meeting Texas Medical Association, section on Allergy Asthma and Immunology, San Antonio, Texas, May 27, 2000. “Safe and Appropriate Uses of Immunotherapy.”

Medical Grand Rounds, Mayo Clinic, Rochester, MN, June 7, 2000 “Update on Allergic Immunotherapy”

IWAA #3rd Annual Scientific Session, Park City, UT, (1) What comes first? “Nasal steroids or antihistamines”, June 30, 2000, (2) “Does bronchodilator therapy control Asthma?”, July 1, 2000

XXIV Annual Meeting, Argentine Allergy-Immunology Society, Buenos Aires Argentina, (1) “Asthma and Immunology, Allergy Progress”, (2) “Management of patients with severe asthma”, August 18, 2000. Non traditional ways of immunotherapy: Do they work, are they safe?”, August 18, 2000

Glaxo-Wellcome National Specialist Summit Meeting, Chicago, IL “Clinical Rationale for Use of an Inhaled Corticosteroid with a long-acting Beta Agonist”, September 16, 2000

Medical Grand Rounds, New York, “Asthma Guidelines and Outcomes”. September 26, 2000

Texas Asthma Coalition Meeting, Keynote speech, October 10-11, 2000, Austin, Texas

American College of Allergy, Asthma & Immunology Annual Meeting, Seattle, WA. November 2000. Workshop: (1) “Allergen Treatment: Optimal Dose,” (2) “Role of Intranasal Steroids in Allergic Rhinitis,” (3) “Future Implications for Asthma Therapies: Fulfilling Unmet Patient Needs,” (4) Literature Review Course: Allergen Immunotherapy,”

The Family Practice, Chief Resident’s Meeting, Phoenix, Arizona, November 16-19, 2000. “Asthma Treatment Plans.”

Southwest Allergy Forum (SWAF) & Eastern Allergy Conference (EAC), January 10–14, 2001 “Combination Therapies in Asthma,” “Present and Future Advances in Immunotherapy.”

Western Society of Allergy, Asthma & Immunology, Lanai, Hawaii, January 21-25, 2001. “Long-Acting Beta-Agonists.”

ACP/ASIM Colorado Chapter Annual Meeting, Colorado Springs, Colorado, February 2, 2001. “The Dripping Nose.”

ACP/ASIM Annual Session 2001, Atlanta, GA, March 28, 2001. “The Role of Diagnostic Testing and Allergen Immunotherapy in the Treatment of Allergic Rhinitis and Bronchial Asthma.”

Recent Advances in Anti-histamines Therapy, New Orleans, LA, March 15, 2001. “Prospects for Anti-histamines in the treatment of asthma.”

American Academy, Allergy, Asthma & Immunology, New Orleans, LA. March 18, 2001. Dinner Symposium “Immune Therapy. What does the future hold?”

John’s Hopkins: Advanced Studies in Medicine – Pulmonary Fellows Conference. San Francisco, CA. May 18, 2001. “Combination Therapy for Asthma.”

Intermountain West Allergy Society, Coer d’Alene, ID, 13–15 July 2001. “Safety Factors for Inhaled Corticosteroids,” and “Combination Therapy of Asthma.”

Current topics in Allergy and Clinical Immunology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, October 5, 2001. “Evidence-based immunotherapy: The why, the when and the how.”

3rd Annual Elliott Middleton Lecture. Allergy-Immunology Society of Buffalo, NY, November 1, 2001. “Present Status of Immunotherapy.”

American Academy of Allergy, Asthma & Immunology, Family Practice Chief Residents Meeting, Phoenix, Arizona, Nov. 8-11, 2001. “Asthma Treatment Plans.”

American College of Allergy, Asthma and Immunology. Annual Meeting. Orlando, FL November, 2001. Literature Review: Immunotherapy

Dinner Symposium: Beta-Agonist Therapy of Bronchial Asthma

Workshop: Practical Prescription Writing

Plenary: Immunotherapy: Who are the Right Patients?

American Academy of Allergy, Asthma & Immunology Annual Meeting, New York, NY, February 28, 2002.

Dinner Symposium: Asthma Therapy: Which Combination is Best?

Association of Military Allergists: Immunotherapy in Clinical Practice.

Workshop: Practical Allergy Prescription Writing.

Asthma, Allergy & Immunology Fingerlakes Medical Conference, Binghamton, NY, April 6, 2002.

1) Combination Therapy of Asthma

2) Indoor/Outdoor Allergens.

American College of Physicians Annual Meeting, Philadelphia, PA, April 11, 2002. Evening Symposium: "New Prospects on the Management of Asthma."

Boston City-Wide Allergy/Immunology Rounds, Boston, MA, April 23, 2002. The Link Between rhinitis and Asthma.

Mayo Clinic, Scottsdale, AZ, May 3, 2002. Medical Grand Rounds: Clinical Aspects of Immunotherapy.

Children's Hospital, Miami, FL, May 7, 2002. Pediatric Grand Rounds: Clinical Aspects of Immunotherapy.

9th Annual Allergy Fellows Symposium, Atlanta, GA, May 16, 2002. Guidelines for Asthma: What Have We Learned?

Allergy/Immunology Society of Vancouver, Vancouver, BC, Canada, May 29, 2002. Optimal Immunotherapy.

American Association of Certified Allergists, MS Rotterdam, July 1-2, 2002.

- 1) Rhinitis-Asthma Link
- 2) Mild Persistent Asthma: What is the Best Treatment?

25th International Conference on Pediatric/Adult Allergy and Clinical Immunology, Toronto, Ontario, Canada, July 19 & 20, 2002.

- 1) Combination Therapy for Asthma
- 2) Immunotherapy for Allergic Respiratory Diseases.

Arizona Allergy and Asthma Society, Sedona, Arizona 18 August, 2002.

- 1) Immunotherapy: Clinical Update
- 2) Immunotherapy: Use of Standardized Extracts for Optimal Dosing.

First Mid-East Congress of Allergy and Immunology, Beirut, Lebanon September 6 and 7, 2002.

- 1) Combination Therapy for Optimal Control of Asthma
- 2) Workshop on Allergy Diagnosis".

University of South Florida, Tampa, Florida. October 1 & 2, 2002. "Optimal Immunotherapy", "Beta-Agonists."

San Diego Allergy Society. 7 October, 2002."Optimal Immunotherapy"

Northern California & Sacramento Allergy Societies, Livermore, CA. 19 October, 2002. "Optimal Immunotherapy"

Annual Meeting, American College of Allergy, Asthma and Immunology. San Antonio, TX Nov14-19, 2002.

- 1) Use of Beta-Agonists in the Treatment of Asthma
- 2) Mild Asthma: When to Treat and How Much.
- 3) Literature Review Course:: Immunotherapy
- 4) Workshop: Allergen Treatment: Optimal Dose
- 5) Workshop: Allergen Skin Testing
- 6) NHLBI Update to the Guideline for the Diagnosis and Management of Asthma.

Western Society of Allergy and Immunology, Maui, Hawaii, January 20-24, 2003:

- 1) Asthma, Can It Be Prevented?
- 2) Optimal Skin testing

American Academy of Allergy, Asthma and Immunology, Denver, Colorado. 8-12 March, 2003.

- 1) Anaphylaxis from Richet & Portier to the Present
- 2) Optimal skin Testing

Wm Beaumont Army Medical Center (Grand Rounds) 11 April, 2003. Update on Allergen Immunotherapy.

American Thoracic Society Seattle, Washington 16 May, 2003. Postgraduate Course:
Clinical Recognition of the Role of Allergy in Airway Disease. Symposium presentation: “What are the relevant outcomes measures in clinical trials that predict success in the management of asthma?”

Korean Allergy Congress, 30-31 May, 2003.

Education Strategies for improved asthma care:”

Symposium: Novel advances in pharmacotherapy for atopic diseases,

- 1) Add –on therapy;
- 2) Immunotherapy for atopic diseases: present and future.

Florida Allergy, Asthma and Immunology Society, Annual meeting. Orlando, Florida 13-15 June 2003.

- 1) Understanding the Upper and Lower Airway Connection
- 2) Optimal Immunotherapy

Asthma 2003, Washington, DC 18-21 June 2003.

What we know about allergy and asthma

Pennsylvania Society of Allergy and Immunology, Hershey, PA 20-22 June 2003

- 1) Optimal Immunotherapy
- 2) Step Treatment of Asthma: The Evidence Behind the Guidelines.

California Society of Allergy, Asthma & Immunology. Annual Meeting. Napa, California. August 8-10, 2003.

- 1) Immunotherapy, Does it Work for Asthma?
- 3) Allergy Vaccine:” Optimal Dose.

World Allergy Organization Congress – Vancouver, British Columbia, Canada. 7-12 September, 2003

- 1) Platinum Symposium 10 September: Optimizing Dual Therapy for Asthma: The Clinical Trials
- 2) Interactive Workshop 11 September: Asthma in Adults

7th Annual Meeting of the Arab Thoracic Association. Beirut Lebanon 9 October 2003.

Satellite Symposium: ASTHMA: The Achievement of Full Control.

Annual Meeting American College of Allergy Asthma and Immunology. New Orleans, LA November 7-12, 2003.

Literature Review Course: Allergen Immunotherapy.

Workshop: Optimal Skin Testing

Pro/Con Plenary Session: Leukotriene antagonists are the best agents for the initial treatment of mild asthma (Con)

Immunotherapy Collegium Keynote Address: Immunotherapy: Doing It Right!

Indiana Society Allergy and Immunology. Indianapolis, Indiana 9 January 2004

Ten Influential Allergy Articles.

Sixtieth Annual Meeting American Academy of Allergy Asthma and Immunology, San Francisco, California, March 19-23, 2004.

Clinical Research Afternoon Symposium (19 March) “Assessing Protocol Feasibility”

Skin Testing and Immunotherapy: The Basics and Beyond, part I. (19 March) “Allergen Vaccine Formulation and Optimal Dose

Workshop: NAEPP Expert Panel Report: Managing Asthma during Pregnancy: Recommendations for Pharmacological Treatment Update 2004.

Workshop: Conventional Immunotherapy Prescription Writing. Single or Multiple Allergens? (20 March) “American View”

Workshop: Asthma Disease Severity: A Prologue to Guideline Implementation (22 March) “Are there Differences between Mild and Moderate Persistent Asthmatics?”

Supper Symposium: Therapeutic Differences Among short Acting B₂ Agonists: A review and Pro/Con Debate. (22 March). “Appropriate Use of Long and Short Acting Beta Agonists in the Treatment of Asthma.”

20th National Congress on Allergy and Immunology 2004. Bangkok, Thailand April 29-30, 2004.

29 April: 1) Step Treatment of Asthma: The Evidence Behind the Guideline Recommendations

30 April: 1) Allergen Immunotherapy Present and Future.
3) How to write a prescription for immunotherapy

Greater Houston Allergy Society Visiting Professor to Baylor University School of Medicine (Houston, TX) and University of Texas Medical Branch (Galveston, TX): 18-19 May, 2004.

“Allergen immunotherapy - Optimal Dosing and Mixing of Vaccines”.
“Allergen immunotherapy – present and future”.

Oregon Allergy and Asthma Society. Portland, OR 2 May, 2004.
“Allergen Immunotherapy – Current Status and Future Outline”

Long Island Allergy and Asthma Society, annual meeting. Montauk Point, NY September 11 & 12, 2004
“Immunotherapy, Present and Future”
“Asthma Control,, Can It be Achieved?:”

Annual Meeting American College of Allergy, Asthma and Immunology. Boston, Massachusetts. November 11-16, 2004

Immunotherapy Collegium II. Presentation: “When to begin immunotherapy: Interventions in childhood”

Breakfast Symposium – Novel Approaches to Modulating the Inflammatory Response in Chronic respiratory Diseases:

Presentation: ”Targeting airway inflammation: The shotgun approach.”

Annual Literature Review: Presentation: “Immunotherapy”

Workshops:

“Immunotherapy prescription writing”

“Advanced Skin Testing”

Annual Meeting American Academy of Allergy Asthma and Immunology. San Antonio, Texas 18-21 March 2005:

Course: Skin testing and immunotherapy: The Basics and beyond 18 March:

Presentation: Extract Stability

Workshop: Advances in Allergen Standardization: Impact on Today’s Practice of Allergy:

Presentation: Optimal dosing for successful immunotherapy.

New England Allergy Society, Spring Meeting 2005. Marlboro, MA 1 April 2005

“Present and Future Trends in Immunotherapy”

Louisville, KY Children’s’ Hospital Annual Allergy Symposium 13 May, 2005

“When to begin Immunotherapy”

“Anaphylaxis from Richet & Portier to the Present”

Kentucky Allergy Society Annual Meeting, Belterra, IN 14 May, 2005

“Allergen Immunotherapy: Present and Future”

“ Asthma Control: Is it Achievable?”

World Allergy Organization Congress, Munich Germany June 26-Jul 6 1, 2005.

American Academy of Allergy, Asthma and Immunology Symposium “Allergen-Specific Immunotherapy”.

Presentation: Immunotherapy in North American: State-of-the-Art.

Oregon Allergy Society. Portland Oregon 1 October 2005

Safety and Efficacy of Allergen Immunotherapy.

Allergy Immunotherapy: State of the Art. Mexico City, October 21-22, 2005.

1) Indications for immunotherapy. Why, who and how?

2) Injection versus sublingual IT.

China Allergological Society. Nanjing, China October 28-29, 2005.

1) An Approach to Effective Immunotherapy

2) Effective Prescription Writing for Allergen Immunotherapy

Annual Meeting American College of Allergy, Asthma and Immunology. Anaheim, California November 4-9 2005.

4 November: Literature Review Course: Immunotherapy

Workshop: Allergen Immunotherapy: Writing an Optimal Prescription.

5 November: Plenary Session: Point-Counterpoint: Which is the Better Way? Subcutaneous Immunotherapy is Better.

6 November: Workshop: Allergen Skin Testing

9 November: Plenary: Use of Fungal Extracts in Allergy Diagnosis and Immunotherapy.

Western Society of Allergy, Asthma and Immunology. Manele Bay, Lanai, Hawaii January 22-26, 2006

New Directions in Allergen Immunotherapy

Rhinitis: What Works and How Well, and What is on the Horizon?

Annual Meeting American Academy of Allergy, Asthma & Immunology. 3-8 March 2006, Miami Beach, FL

Effective Prescription Writing for Allergen Immunotherapy

Best of the Journal of Allergy and Clinical Immunology for 2005

Optimum dosing for Successful Immunotherapy

Massachusetts General Hospital, Allergy/Pulmonary conference Boston, MA. 31 March, 2006.

“Is there a problem with long-acting beta-agonists?”

Blue Grass Allergy Society, Lexington, KY 22 April 2006

“Is there a problem with long-acting beta-agonists?”

“Guideline Directed Therapy of Asthma”

Greater Pittsburg Allergy Society, Pittsburg, PA 2 May 2006

“Is there a problem with long-acting beta-agonists?”

Allegheny General Hospital, Pittsburg, PA 3 May 2006.

“Is there a problem with long-acting beta-agonists?”

16th Venezuelan Congress of Alergia, Asma e Inmunologia, Isle Margarita, Venezuela 17-20 May, 2006

- 1) Problems with the long-acting, inhaled beta₂ agonists?
- 2) When and how to utilize combination inhaled therapy.

Florida Allergy, Asthma & Immunology Society 2006 Annual Meeting. Orlando Florida 9 June 2006.

Are Small Airways Important in Asthma?

Frontiers in Research and Clinical Management of Asthma and Allergy: 20th Annual Update. Johns Hopkins Asthma and Allergy Center 10 June 2006.

- 1) Is there a problem with long-acting beta-agonists therapy? A re-examination of the findings of the SMART study.
- 2) Sublingual Immunotherapy.

26th Annual Summer Meeting: Asthma and Allergy Society of Virginia. Virginia Beach, VA. June 16-18th 2006.
LABA and the SMART study.

University of Michigan, John M. Sheldon Allergy Society Summer Meeting. Boyne Mountain, Michigan July 8-9, 2006

The John M Sheldon Memorial Lecture: Difficult to Control Asthma: Weighing in On Therapeutic Options.

Intermountain West Allergy Association. Annual Meeting. Sun Valley, Idaho 21-3 July, 2006

- 1) Toward Optimal Immunotherapy.
- 2) Is there a problem with long-acting inhaled beta-agonists?

24th John C Selner Aspen Allergy Conference. Aspen, Colorado July 25-29th 2006

The Richard Farr Lecture: Current and Future Status of Allergen Immunotherapy

Pennsylvania State School of Medicine, Hershey, PA 5-6 September, 2006.

- 1) Pulmonary Rounds: Is There a Problem with the Long-acting, beta-agonists?
- 2) Allergy/Immunology Rounds: Allergen Immunotherapy: Present and Future.

Missouri Allergy Society, St Louis, Missouri. 14 September, 2006.
Is there a problem with long-acting inhaled beta-agonists?

Buffalo, NY 21-22 September, 2006.

Buffalo General Hospital Grand Rounds, Buffalo Children's Hospital Pulmonary Conference and Buffalo Allergy Society: Is there a problem with long-acting inhaled beta-agonists?

Buffalo Children's Hospital Allergy Conference: Practical Immunotherapy:

Symposium: Optimization en el Manejo del Asthma. Caracas, Venezuela 30 September 2006.

- 1) Problema con los Beta2-agonistas de Accion Prolongada.
- 2) Cuando y Como USAR terapia combinada?

Gunderson-Lutheran Clinic, Lacrosse Wisconsin 13 October 2006

- 1) Medical Grand Rounds: "Asthma Guidelines, Past, Present and Future"
- 2) Wisconsin Asthma Alliance: keynote address: "Asthma Guidelines, Past, Present and Future".

Philadelphia Allergy Society, 17 October 2006

Is there a problem with long-acting beta-agonists?

Children's Hospital of Philadelphia, 18 October 2006

Present and Future Status of Immunotherapy

Kaiser Permanente 2006 Fall Allergy Symposium. October 21, 2006. Emeryville, California

- 1) What's Hot in Asthma?
- 2) Allergen Immunotherapy: Present and Future.

American College of Chest Physicians, Salt Lake City, Utah, 25 October 2006

Pro:Con debate: Are Long-Acting Beta-Agonists Safe? Pro.

American College of Allergy, Asthma and Immunology. Annual Meeting. Philadelphia, PA November 10-14, 2006

Literature Review Course: Immunotherapy

Plenary Session: Immunotherapy: The Present: Subcutaneous

Great Asthma Raft Debate 2006, Controller Therapy for Asthma: Long Acting Beta Agonists

Clinical Controversies: Point/Counterpoint: Long Acting Beta Agonists are Safe- Pro

Writing Prescriptions for Immunotherapy Vaccines: Workshop. Writing an optimal Prescription.

British Thoracic Society: Winter Meeting December 6-8, 2006. London, England

Symposium: Risks and Benefits of Asthma Drugs

Is there a problem with inhaled long-acting beta2-agonists?

16th Annual British Columbia Thoracic Society/ British Columbia Society Allergy and Immunology. Vancouver, BC, Canada 26-27 January 2007

- 1) Immunotherapy: Present and Future.
- 2) Risk/benefit ratio for inhaled corticosteroids with or without long-acting beta-agonists in asthma
- 3) Immunotherapy: Overview.

American Academy of Allergy, Asthma & Immunology, 2007 Annual Meeting. February 23-7, 2007, San Diego, California.

- 1) Course: Allergy Diagnostics and Immunotherapy: The Nuts and Bolts of an Allergy Practice. Presentation: Allergen Immunotherapy, "Conventional" Immunotherapy. Preparing Effective Immunotherapy Vaccines. What Does it Take?
- 2) Pro:Con Debate: Routine Intradermal Skin Testing Offers Benefit in the Diagnosis of Rhinitis and Asthma. Presentation: Con
- 3) Dinner Symposium: The New NAEPP Asthma Guidelines: Practical Implications for Clinicians. Presentation: Allergen Specific Management in the Guidelines.

Puerto Rican Society of Pulmonology Symposium New Trends in Asthma and COPD...Focus on Total Control.
31 March 2007, San Juan, Puerto Rico,

“The 2007 Revision of the NHLBI Asthma Guidelines”

Medical Grand Rounds, University of Nebraska Health Sciences Center, Omaha, Nebraska 26 April 2007:

“2007 Update on the NHLBI Asthma Guidelines”

Richard Cushing Memorial Lecture for the American Lung Association of Minnesota. Minneapolis, MN 1 May 2007:

“2007 Update on the NHLBI Asthma Guidelines”

Medical Grand Rounds, Hennepin County Medical Center, Minneapolis, MN 2 May 2007:

“Is There a Problem with Long—Acting Beta-Agonists?”

Focus on: Asma ed Allergia. Taormina Italy 11-14 May 2007.

“ Immunotherapy in the United States, differences from Italy”

Florida Society of Allergy, Asthma and Immunology. Sarasota, Florida 8 June, 2007.

Is there a problem with long-acting beta-agonists? A reexamination of the SMART study.

Aspen Allergy Conference, Aspen Colorado 24-8 July, 2007

“Asthma at the Aspen Allergy Conference”

Pulmonary, allergy, Critical Care and Sleep medicine, 3rd Annual Conference. Wayne State University School of medicine, Boyne Mt, Michigan August 16-19, 2007.

“ The 2007 Update of the Asthma Guidelines”

Greater Washington Allergy Society: 26 September 2007:

“The New Asthma Guidelines”

Walter Reed Army Medical Center: 27 September, 2007:

“Sublingual Immunotherapy”

Southeastern Allergy Immunology Society, Annual Meeting. Williamsburg, Virginia 5-6 October, 2007

“The New Asthma Guidelines”

“Current Status of Allergen Immunotherapy”

II Immunotherapy Course: The Insights of Effective Vaccines for Allergy. Mexico City 12-13 October 2007

“Immunobiology of Allergens: What Makes an Allergen an Allergen”.

“Airway Remodeling: Can We Stop it with Immunotherapy?”

American College of Chest Physicians, annual meeting, Chicago, Illinois October 21-5, 2007.

Joint ACCP/AAAAI session: “The Role of Sublingual Immunotherapy in Allergic Asthma and Rhinitis.”

American College of Allergy, Asthma and Immunology. Annual meeting. Dallas, Tx. November 9-14, 2007

Literature Review Course: “Immunotherapy 2007”

Plenary Sessions: “ The World According to Hal”

NLHBI Asthma Guidelines Update: “Environmental Factors and Co-Morbidities”

World Allergy Congress, Bangkok, Thailand 2-6 December, 2007.

Specific Immunotherapy Symposium, Interactive workshop: “Which patients? Which regime?, Meet the expert:” Immunotherapy”

Symposium: Asthma Mortality: “Do Long-acting beta-agonists cause asthma death? A beta-agonist deja-vu?”

Stanford University Pulmonary/Allergy Grand Rounds. 8 January, 2008.

Update on the 2007 Asthma Guidelines.

Western Society of Allergy, Asthma and Immunology. Hawaii, Hawaii January 21-5, 2008
2007 Asthma Guidelines: What's New, What's Not.
Allergen Immunotherapy: Optimizing Treatment, Future Directions.

Broward County Allergy Society. Ft. Lauderdale, FL. 22 February 2008.
2007 Asthma Guidelines: What's New, What's Not.

American Academy of Allergy Asthma and Immunology, annual meeting, Philadelphia, PA 12-17 March 2008.
1) Association of Military Allergists 12 March. Immunotherapy: State of the Art.
2) Course: 13 March Conventional Immunotherapy: Preparing effective immunotherapy vaccines, what does it take?
3) Common Noteworthy Issues in Allergy for the Primary Care Provider. 15 March.
"Immunotherapy: SCIT vs SLIT."
4) Workshop: When and How to Change the Course of Immunotherapy. 15 March.

AAAAI/ACAAI Certification/Maintenance of Certification Board Review Course. Chicago IL April 18 2008.
Allergen Immunotherapy

University of Wisconsin, Madison. Medical Grand Rounds. 30 April 2008
Allergen Immunotherapy: Current Status and Future Directions.

University of Florida, Jacksonville, Pediatric Grand Rounds. 7 May 2008
The New NHLBI Asthma Guidelines.

Peking Union Medical College, Beijing, China. 3 June 2008. Special Seminar.
Allergy Immunotherapy: Current Status.

29th Annual Postgraduate Course. The Alabama Society of Allergy, Asthma and Immunology. Destin, Florida. August 8-10, 2008.

Update on LABAs
Present and Future of Allergen Immunotherapy.

Annual Meeting, Allergy and Asthma Foundation of Alaska. Grinwood, Alaska 12-13 September, 2008.
2007 Update of the NHLBI Asthma Guidelines.

Greater Kansas City Allergy Society. Kansas City, Missouri 16 October 2008
New Advances in Immunotherapy: Omalizumab and SLIT

University of Kansas Medical Center, Kansas City, Kansas. Pediatric Grand Rounds 17 October 2008.
2007 Update of the NHLBI Asthma Guidelines.

American College of Allergy, Asthma and Immunology. Annual Meeting Seattle, Washington November 6-11th 2009.
6 November, Tracking Oral Immunotherapy: "The U. S. Inexperience. A View from Hal."
7 November, Annual Literature Review: "Immunotherapy 2008"
8 November, Sublingual Immunotherapy for Allergic Rhinitis: The Latest Evidence: "Long-term Studies with SLIT"

American Academy of Allergy, Asthma and Immunology. Annual meeting. Washington, DC, March 13-17, 2009.
Preparing Effective Vaccines for Injection Immunotherapy.
Workshop: When and How to Change the Course of Immunotherapy.

First Middle East-Asia Allergy Asthma Immunology Congress. Dubai, UAE 26-9 March 2009/
Keynote Address: Controversies on Long Acting Beta-agonists.
New Modalities of Immunotherapy
Meet the Professor: Immunotherapy
Workshop: Preparing an Effective Subcutaneous Immunotherapy Vaccine.

Intermountain West Allergy and Asthma. Sun Valley, Idaho July 16-19, 2009

Immunotherapy Master class
Asthma Management – Beyond the Guidelines

27th John Selner Aspen Allergy Conference. 28 July-1 August 2009.
Overview of SLIT vs. SCIT

Annual Meeting Canadian Society of Allergy and Clinical Immunology, Halifax, Nova Scotia October 23rd 2009.
Royal College of Physicians and Surgeons of Canada lecture: “Update on Immunotherapy in the 21st Century – From Subcutaneous to Sublingual”

Annual meeting American College of Allergy, Asthma and Immunology. Miami Beach, FL November 6-10, 2009
Immunotherapy Literature Review 2009.

XXI World Allergy Congress 2009. Buenos Aires, Argentina 6-10 December 2009
Immunotherapy 2009 – Where we are and unmet needs.
How to use multi-allergen IT
Immunotherapy for asthma Pro in Pro-Con debate.

48th Scientific Session Western Society of Allergy, Asthma & Immunology. Lanai, Hawaii 24-28 January 2010.
Workshop: Practical Approach to Immunotherapy.
Lecture: The Future of Allergen Immunotherapy
Lecture: Asthma Guidelines: Where Do We Go From Here?

Annual meeting: American Academy of Allergy, Asthma and Immunology. New Orleans, LA February 26-March 2, 2010.

Course: Allergy Diagnostics and Immunotherapy: The Nuts, the Bolts, the Science and the Art.
Presentation: Safety and Efficacy of Subcutaneous Immunotherapy.

ACAAI/AAAAI Board Review Course. Chicago IL April 15-18, 2010
“Allergen Immunotherapy”

Louisiana Allergy, Asthma and Immunology Society, Annual Meeting, New Orleans, LA June 11-13, 2010.
SLIT and New Approaches to Allergen Immunotherapy

California Society of Allergy, Asthma and Immunology 18th Annual Educational Meeting July 9-11, 2010 - San Francisco, CA

Is the US ready for SLIT?
Update on LABA Safety.

Beth Israel Medical Center, New York, NY. 21 September 2010.
Department of medicine Grand Round: Update on Bronchial Asthma.

Long Island Allergy and Asthma Society. 17th Annual Scientific Conference, Montauk, N.Y. 24-26 September 2010
Immunotherapy: SLIT and SCIT, Rush and Cluster.
The Long-Acting Beta-Agonist Controversy

Los Angeles Society of Allergy, Asthma and Clinical Immunology, 2010 Fall Symposium
October 2, 2010, Los Angeles CA.
New Developments in the Long-Acting Beta-Agonist Safety Controversy.

Finger Lakes Allergy Society, Rochester, NY, October 6, 2010
John J. Condemni Annual Lecture: “The Long-Acting Beta-Agonist Controversy”

International Conference on Specific Immunotherapy: State of the Art and Perspectives. Taormina, Sicily, Italy 24-26 October 2010.

A historical overview of immunotherapy.
Expanding the role of sublingual immunotherapy: Critical aspects
Sublingual immunotherapy in the United States: The heterogeneity of allergen exposure.

Annual Meeting, American College of Allergy, Asthma and Immunology. Phoenix, Arizona 11-16 November, 2010.
Thursday Pre-Meeting Course: SLIT in the U.S. – Using the evidence.
Literature Review Course – Immunotherapy
Plenary Session – The World According to Hal II: A Hundred Years of Immunotherapy.

World Allergy Organization, Dubai, 6-8 December 2010
Post-Graduate Courses:
Optimizing asthma management and treatment through behavior modification
Practical aspects of immunotherapy
Plenary Session:
Asthma and pregnancy
Symposium:
Subcutaneous immunotherapy

Annual meeting, American Academy of Allergy, Asthma and Immunology. San Francisco, California, March 18-22 2011.
Course: Allergy Diagnostics and Immunotherapy: The nuts, the bolts, the science and the art. Presentation: “Allergy Immunotherapy in the Present: Optimizing the Efficacy and Safety of subcutaneous Immunotherapy.
Symposium: 100 Years of Allergy Immunotherapy; Past, Present and Future. Presentation: “The History of Allergy Immunotherapy: overview, Landmark Events and lessons Learned.”

III Curso Nacional de Immunoterapie. San Juan del Rio, Qro., Mexico 13 & 14 May 2011.
T-cell Immunoregulation and the Response to Immunotherapy
New Approaches to allergen Immunotherapy
Anti-IgE in Asthma and Other Allergic Diseases

13th International Paul-Ehrlich-Seminar: Allergen Products for Diagnosis and Therapy: Regulation and Science. Washington, DC September 14-17, 2011
Opening keynote Address: History of Specific Immunotherapy (SIT)

South East Allergy Forum. Grand Point, Alabama, 16-17 September, 2011.
One Hundred Years of Immunotherapy and Beyond.

American College of Allergy, Asthma and Immunology, Annual Meeting, Boston, MA November 4-8, 2011.
Literature Review: Immunotherapy.

World Allergy Conference. Cancun, Mexico. December 4-8, 2011.
Which Patients for Subcutaneous Immunotherapy?
Use of Multiple Allergen Mixes in Immunotherapy.

Western Society of Allergy, Asthma & Immunology, 550th Annual Scientific Session, Koloa, Kauai, Hawaii January 22-26, 2012.
New Insights in Local Allergic Rhinitis
Unanswered Questions after 100 Years of Immunotherapy.

Allergy, Asthma, Immunology Foundation of Northern California. Annual meeting, San Francisco, CA 11 February, 2012.
The Abba Terr Lecture: The Future Direction of Immunotherapy.

Annual Meeting American Academy of Allergy, Asthma, and Immunology. Annual Meeting, Orlando, FL 2-6 March 2012.
Fellows-in-Training Session.
Immune Modulation by Immunotherapy

New Jersey Allergy Society. Evening meeting 19 March 2012
Future Directions in Immunotherapy.

New Jersey School of Medicine and Dentistry, Newark, NJ. 20 March 2012
Medical Grand Rounds. Update on the Diagnosis and Treatment of Asthma.

Annual meeting Allergy, Asthma & Immunology Society of Georgia 4-5 May 2012
1) 2nd Betty Wray Lecture: Immunotherapy Advances & Standardization
2) SLIT

Annual meeting Pennsylvania Allergy Association. Hershey, PA, June 22-4, 2012
Is there a problem with Long-Acting Beta-Agonists?
One Hundred Years of Immunotherapy, What are the unanswered questions?

Intermountain West Allergy Society. Annual meeting, Sun Valley, Idaho. 28-30 June 2012.
What's New in Subcutaneous Immunotherapy?
Update on SLIT- is it ready for Clinical Practice in the US?

Kaiser-Permanente of Northern California, annual allergy/immunology symposium
Berkeley, California 6 October 2012:
1. Sublingual immunotherapy
2. New and future approaches to immunotherapy
3. Immunotherapy schedules: Cluster and Rush.

Canadian Society of Allergy, Asthma and Clinical Immunology. Annual meeting, Calgary, AB, Canada. 11-14 October 2012.
1. Immunotherapy: New Approaches using current allergen extracts.
2. **The Bram Rose Memorial Lectureship:**
Immunotherapy: Alternatives to subcutaneous and oral routes.

Greater Kansas City Allergy Society, Annual Symposium 2013, January 12, 2013
Update on Immunotherapy

California Society of Allergy, Asthma and Immunology: A Midsummer Night's Wheeze 2013. Hyatt Regency, Huntington Beach, California June 28-30, 2013.
Alternative Routes of Immunotherapy
The Asthma Epidemic: Possible Causes.

American College of Allergy, Asthma and Immunology annual meeting. Baltimore, MD . November 8-11, 2013.
Annual Literature Review: Immunotherapy

American Academy of Allergy, Asthma and Immunology. Annual meeting, San Diego, CA Feb 28-March 4, 2014.
Session: Allergen Immunotherapy: The Nuts and the Bolts.
SCIT and SLIT: Optimal Dosing Regimen and Duration

Eastern Allergy Conference. Palm Beach, FL 29 May-1 June 2014.
New Forms of AIT for Rhinitis and Asthma

Immunoterapia IV: State of the Art 2014. 26-27 September, Mexico City, Mexico.
CD4 Lymphocyte Subsets in allergic Inflammation
Use of Multiple Allergen Mixes in Immunotherapy

Annual Meeting, American College of Allergy, Asthma and Immunology. Atlanta, Georgia November 7-10, 2014.
Immunotherapy: (Annual Literature Review).
Is it time to "retire" conventional SCIT? SLIT drops, rush and cluster SCIT. (Plenary Session).

American College of Allergy, Asthma and Immunology Webinar 22 January 2015
Is SLIT ready for America?

Christian Medical College Hospital, Vellore TN, India. Webinar 23 March 2015:
Update on Immunotherapy

Florida Allergy, Asthma and Immunology Society, Annual Meeting. Orlando, Florida July 17-19, 2015.
Sublingual Immunotherapy with House Dust Mite Extracts
Environmental Risks for Developing Asthma.

XXII Congreso Nacional de Alergia, Asma e Inmunologia Pediatricase. Ciudad de Mexico July 22-25, 2015.
Tertiary Intervention: Allergen Immunotherapy in Pediatric Asthma
Perinatal Programming of Allergic Diseases: Role of the Intestinal Microbiota

XXIV World Allergy Congress. Seoul, Korea 14-17 October 2015.

Evidence in immunotherapy: Sublingual Immunotherapy (SLIT) vs. Subcutaneous Immunotherapy (SCIT)
Addressing the shortcomings of Subcutaneous Immunotherapy (SCIT)

Annual Scientific Meeting, American College of Allergy, Asthma & Immunology. San Antonio, Texas, November 5-9, 2015

Literature Review: Immunotherapy
Altering the natural history of allergic diseases with immunotherapy: SCIT and SLIT in Everyday Practice: Current Best Practice.

Annual meeting American Academy of Allergy, Asthma and Immunology. Los Angeles California, March 4-7, 2016.

SLIT Practical Considerations, Unmet Needs and FAQs.
Interest Section Business Meeting: SLIT and SCIT: Alternatives or Rivals? SLIT and SCIT: What Should We Use?

Allergy, Asthma, and Immunology Society of South Carolina, 2016 Annual Meeting. Charleston, South Carolina March 18-20, 2016

What's New Beyond SLIT and Current SCIT?
Risk Factors for New Onset Asthma

Christian Medical College Hospital, Vellore TN, India. Webinar 23 March 2015:
Update on Immunotherapy

Eastern Allergy Conference, Palm Beach, Florida 3-5 June 2016
Immunotherapy: Now and in the Future

Northwest Allergy forum, Seattle, Washington, 22-23 October 2016

New Approaches to Immunotherapy: Beyond SCIT and SLIT
Gail G. Shapiro Memorial Lecture: The Current Status of sublingual Immunotherapy

American College of Allergy, Asthma and Immunology. Annual Meeting. San Francisco, CA 10-14 November 2016.

Immunotherapy Coming of Age – 100 Years and We're Just Getting Started
2016 Literature Review – Immunotherapy
What Separates Allergist from Other Specialists?

Western Society of Allergy, Asthma, and Immunology. Hawaii, Kona January 29 to February 2, 2017.

Current Status of subcutaneous and sublingual Immunotherapy
New Approaches to Immunotherapy: Beyond SCIT and SLIT.

2017 Annual Meeting American Academy of Allergy, Asthma and Immunology. Atlanta, Georgia, 3-6 March

Symposium: Open Wide: Sublingual and Oral Immunotherapy
Presentation: Open Wide: Multiple Allergen SLIT and OIT.

SLIT: Practical Considerations, Unmet Needs, and FAQs.
Three experts, panel discussion

Christian Medical College Hospital, Vellore TN, India. Webinar 23 March 2015:

Update on Immunotherapy

Eastern Allergy conference Palm Beach, Florida June 1-4, 2017

Hot issues in allergy immunotherapy
Choosing laboratory testing “wisely” in allergy and immunology.

Inmunoterapia V. State of the Art 2017. Mexico City, Mexico, 6-7 October 2017

Efficacy of Immunotherapy versus Pharmacotherapy
Multiallergen Immunotherapy: Is it Necessary to Include All Positive Skin Prick and In Vitro Tests?

Annual Meeting: American College of Allergy, Asthma and Immunology. Boston, Massachusetts October 26-30, 2017.

Literature Review Course: Immunotherapy 2017.

Joint Annual Meeting American Academy of Allergy, Asthma and Immunology and World Allergy Organization. Orlando, Florida, March 2-5, 2018.

Symposium: Advances in Aeroallergen Immunotherapy
Presentation: Why Immunotherapy in the USA is Different than Immunotherapy in Europe.

Eastern Allergy Conference, Palm Beach Florida, May 31=June 3, 2018.

Dust Mite Allergy: what works and what doesn't work. AIT.

Allergy/Immunology conference (on line)- COLA. Children's Mercy Hospital, Kansas City, MO.
24 August, 2018 – Principles of Traditional Immunotherapy.

2018 Northwest Allergy Forum. Bellevue, WA September 29-30, 2018

The current status of subcutaneous immunotherapy and how we got there.
Is sublingual immunotherapy the future of allergy immunotherapy?

American College of Allergy Asthma and Immunology. Annual Meeting. Seattle, WA 16-19 November 2018.

What to do when your patient is allergic to multiple allergens for which there are sublingual FDA approved tablets.

Literature Review: Allergy Immunotherapy.

American College of Allergy Asthma and Immunology, Annual Meeting, Houston, Texas 8-11 November 2019.

Literature Review: Allergy Immunotherapy

Colorado Allergy, Asthma Society evening meeting.. 10 December 2019:

'Present Status of Subcutaneous and Sublingual Immunotherapy

American Academy of Allergy, Asthma & Immunology. Virtual Annual Meeting 2020

Update on Mechanisms of AIT (SCIT & SLIT)): Evidence for an Impact on Clinical Efficacy.

Kansas City Children's Hospital (by internet) 17 July, 2020.

Present Status of Subcutaneous Immunotherapy

American College of Allergy Asthma and Immunology, Annual Meeting, Virtual, 13-15 November 2020

Are You Dosing Properly?

Literature Review: Immunotherapy

Asthma Allergy Certification Course. 29 December 2020.

Status of Subcutaneous and Sublingual Immunotherapy.

43rd Annual National Jewish Health Pulmonary and Allergy Update, Virtual, 4-5 February 2021

Allergy Immunotherapy: The Recent Literature

American Academy of Allergy Asthma and Immunology, Annual Meeting, Virtual, 26 February-1 March 2021

The Top Five Immunotherapy Articles in the Last 50 Years that Changed Our Practice

Using Component Based Diagnostics and Effective Allergen Doses for Diagnosis and Subcutaneous Immunotherapy Treatment

Kansas City Children's Hospital (by internet) July, 2021.

Present Status of Subcutaneous Immunotherapy

University of Pennsylvania Medical School, Allergy/Immunology Grand Rounds (virtual) 10 September 2021.

PRESENT STATUS OF SUBCUTANEOUS AND SUBLINGUAL IMMUNOTHERAPY.

Rutgers University Medical School, Allergy/Immunology Grand Rounds (virtual) 30 September 2021.

PRESENT STATUS OF SUBCUTANEOUS AND SUBLINGUAL IMMUNOTHERAPY.

Annual meeting American College of Allergy, Asthma and Immunology. New Orleans, LA November 5th, 2021.

Literature Review: Allergy Immunotherapy

Western Society of Allergy, Asthma and Immunology, Wailea, Maui, HI, February 6-10, 2022

History and Evolution of Allergy Immunotherapy

Factors Effecting Safety and Efficacy of SLIT

American Academy of Allergy, Asthma and Immunology. Phoenix, AZ, February February 25-28, 2022.

Review of Math-free Allergy Prescription Writing.

Eastern Allergy Conference, The Breakers, Palm Beach Florida 2-5 June 2022.

What's New in AIT?

Bacterial Lysate Therapy in Patients with Allergic Diseases.

American College of Allergy, Asthma and Immunology. Annual Meeting. Louisville, Ky. Nov11-14, 2022.

Immunotherapy: Literature Review

The history of Immunotherapy: How did we get where we are?

Mechanisms involved in allergy immunotherapy

Eastern Allergy /conference, The Breakers, Palm Beach FL. June 1-4, 2023.

Immunotherapy with Fungal Extracts

California Society of Allergy, Asthma and Immunology. Annual Meeting. Hyatt Regent, Huntington Beach CA. June 23-25, 2023.

Present status of subcutaneous and sublingual allergy immunotherapy

How important is proper dosing for SCIT and SLIT?

Zoom lecture to Division of Allergy and Clinical Immunology
Department of Medicine, Faculty of Medicine Siriraj Hospital
Mahidol University
Bangkok 10700
Thailand
26 September 2023, 7:00 PM
Allergy Immunotherapy for Respiratory Allergic Diseases

American College of Allergy, Asthma and Immunology annual meeting Anaheim, California.
November 9-13, 2023.

Literature Review: Allergy Immunotherapy.